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Abstract 
 
FimH antagonists are small molecule inhibitors, derived from α-D-mannose, which 
block the adhesion of uropathogenic Escherichia coli (UPEC) to bladder cells. The 
abolition of binding leads to clearance of the bacteria with the urine flow and 
prevents urinary tract infections (UTIs). Within this thesis, the merits as well as 
problems of an anti-adhesive therapy (in the context of the infection cycle of UTI) as 
an alternative approach to combat bacterial infections are described.  
 
Previous reports showed successful applications of FimH antagonists in vitro and in 
vivo. The antagonists reduced bacterial attachment to cells and surfaces and 
decreased bladder infections in a UTI mouse model. Within this thesis, FimH 
antagonists from our group were screened for their minimal anti-adhesive 
concentration (MAC90) using an in vitro cell infection assay. The minimal therapeutic 
concentration was analyzed in the context of the pharmacokinetic (PK) performance 
of individual antagonists. It could be shown, that a preventive application and the 
resulting peak concentration of a FimH antagonist in the urine relative to the MAC90 
value is predictive for positive treatment outcome. Guided by this finding, several 
treatment regimens, including combination therapies with antibiotics, were 
successfully applied to reduce bladder infections in an experimental mouse model by 
up to three orders of magnitude. Furthermore, FimH antagonists were effective 
against catheter-associated UTI (CAUTI), assessed by a newly established 96-well 
screening assay, using catheter pieces and human urine. They prevented biofilm 
formation in concentrations as low as 6.25 µg/ml. Moreover, in all tested 
applications, FimH antagonists exhibited a synergistic effect with ciprofloxacin (CIP), 
implying the possibility of combination therapies. 
 
Antagonizing the FimH lectin proofed cumbersome, because depending on the 
UPEC strain, the FimH binding pocket exhibits different affinity states towards 
mannose ligands. This leads to different MAC90 values for every individual strain and 
a specific antagonist. Besides, different strains vary in their infection course over 
longer time periods, probably related to the different affinity state of the FimH lectin. 
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Consequently, the differences in affinity in combination with the infection time course 
might strongly influence treatment regimens, which will be an important topic of 
future investigations. 
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1.1. Urinary tract infection 
 
Urinary tract infection (UTI) is a highly prevalent infection worldwide, both in the 
community, and in hospital settings. Statistically, 50% of all women endure at least 
one episode of symptomatic UTI in their lifetime. Furthermore, the recurrence rate 
within six months is 25%, of which 3% experience a third UTI episode in the 
following six months.1–3 Thereby, the strain causing a recurrent UTI (rUTI) is often 
genetically identical to the strain that caused the first infection.4–6 
 
Particularly affected are young, sexually active women. By the age of 24, one third 
reported at least one physician-diagnosed UTI with medication prescription.1,7 
Although the incidence is decreasing with age - women in the age group between 
55-59 have the lowest incidence rate with 6.4% - older patients show a longer 
symptom duration.7,8 Overall, Foxman et al. estimated the annual costs of 
community acquired UTI in the United States to be 1.6 billion US dollars. 1,7 
 
A UTI episode is classified as uncomplicated or complicated. An uncomplicated UTI 
occurs in patients with a normal urinary tract anatomy, requires short-term treatment, 
and normally has no future medical consequences. Patients enduring a complicated 
UTI suffer from other co-morbidities, such as anatomical abnormalities in the urinary 
tract, diabetes, immunosuppression, pregnancy, prior pyelonephritis, catheterization, 
or are infected with a multi-resistant strain. Treatment of a complicated UTI is more 
complex and the infection can result in renal damage.1,9,10 
 
In up to 90% of the uncomplicated, community-acquired cases, uropathogenic E. coli 
(UPEC) is the causing pathogen.1,9 It is followed by Staphylococcus saprophyticus 
with incidences between 10-15%, depending on the country.2,11 A complicated UTI 
can also be caused by Klebsiella spp., Enterobacter spp., Serratia spp., and Proteus 
spp., as well as Staphylococci and Enterococci.2,9,10 
 
Uropathogenic bacteria possess several virulence factors that enhance the urologic 
infection potential. One of those, are the bacterial adhesins. 
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1.2. Adhesins as important virulence factors for UTI 
 
UPEC possesses several distinct adhesins, providing the urinary tract colonizing 
advantage. Some of them are not expressed or genetically not encoded on the fecal 
relatives.12  
 
However, type 1 pili (also termed type 1 fimbriae), the adhesin most often connected 
to UTI, is common within the family of Enterobacteriaceae.13–15 Wu et al. were the 
first to report the binding of type 1 pili to uroplakin expressed on the urothelial cell 
surface.16 Adhesion is the first step in the UTI infection cycle, it is mediated by the 
FimH lectin, located at the tip of type 1 pili.17 E. coli isolates expressing type 1 
fimbriae were connected to a higher disease severity compared to non-expressing 
bacteria, resulting in longer bacterial persistence and higher inflammatory responses 
in the urinary tract of children.18  
 
Other important adhesins are the P pili. They are important in more advanced 
infection stages of UTI, especially for developing pyelonephritis.19–21 Four genetic 
classes of PapG were discovered (I-IV).22 Only class II PapG adhesins recognize the 
α-D-Gal-1-4-β-D-Gal pattern of glycolipid receptors expressed in human kidneys.23 
Therefore, class II is specifically associated with upper urinary tract infection.24,25  
 
Both, type 1 and P pili were associated with bacteriuria and are responsible for the 
activation of the host’s immune system.18,26–30 Type 1 pili also bind to the Tamm-
Horsefall-Protein (THP), the most ample glycoprotein in human urine, which contains 
a highly mannosylated moiety.31–33 THP is generated by the epithelial cells lining the 
thick ascending loop of Henle and can be released into the urine. It is assumed to be 
important in the regulation of the electrolyte balance in the urine, but it also modifies 
immune responses and protects against UTI by binding to type 1 fimbriae and 
abolishing attachment to bladder cells.33–36 
 
Further adhesins, such as type 3 fimbriae, S fimbriae, Dr adhesins, Ag43, curli, and 
F1C fimbriae can mediate adhesion in a specific infectious context, inter alia, in the 
urinary tract.19–21 For some of them, the relation to UTI is ambiguous. Still, type 1 
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and type 3 fimbriae, Ag43, and curli are important in biofilm formation, which is a 
central part in the uropathogenic infection cycle (see chapter 1.7.).19,37–39 
 
1.3. Type 1 pili and mannose – the discovery of the importance in 
UTI 
 
In the 1970’s, it was discovered that binding of bacteria to host tissue is a 
prerequisite for an infection. In 1972, Old characterized D-mannose and various 
mannose derivatives as strong inhibitors of type 1 fimbrial dependent 
hemagglutination of guinea pig and horse erythrocytes with Shigella flexneri and 
Salmonella typhimurium.40 Only five years later, Ofek et al. demonstrated a D-
mannose specific adhesion of E. coli to human mucosal cells.41 Several reports 
followed confirming the mannose-dependent binding of type 1 pili; e.g., by Firon et 
al., who studied the inhibition of the binding of E. coli to mannan-containing yeast 
cells by different oligomannosides, or by Neeser et al., who tested plant 
glycoproteins for their inhibitory potential of bacterial adhesion to guinea pig 
erythrocytes and buccal epithelial cells.42,43 
 
In 1978, the connection between type 1 pili and UTI was reported for the first time. 
There was a significant correlation between the presence of fimbriae on E. coli 
isolated from patients with UTI and the adhesion to human urinary tract epithelial 
cells, described by Eden et al.44 Furthermore, over 400 E. coli strains were 
systematically tested for their ability to bind to human urinary tract epithelial cells, 
resulting in the hypothesis that type 1 fimbrial adhesion is a virulence factor selecting 
for uropathogenicity of those isolates.45 In the same period, Aronson et al. used the 
previously established pyelonephritis mouse model by Freedman to test the potential 
of inhibiting a murine bladder infection caused by type 1 fimbriae producing E. coli 
with methyl α-D-mannopyranoside.46 They were able to reduce the occurrence rate 
of UTI by approximately two thirds.47 Ultimately, Hagberg et al. reported a detailed 
study about a reproducible UTI mouse model in 1982, which boosted research in the 
field of UTI.48 Based on these findings and the fact that UPEC defective in type 1 
fimbriae showed 100-1000 fold lower bacterial counts in the bladder, type 1 fimbriae 
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were confirmed as a key virulence factor for the development of UTI in mice.49 
Furthermore, Fujita et al. pictured the binding of E. coli to formalin fixed human 
ureteral epithelial cells from a female patient with a renal cell carcinoma and could 
show the inhibition of bacterial adherence with the addition of D-mannose by 
scanning electron microscopy.50 
 
A single E. coli expresses between 100-500 type 1 fimbriae. They are peritrichously 
arranged, approximately 7 nm in diameter, and between 0.2 to 2 µm long.14,51 Type 1 
fimbriae consist of several subunits, arranged in the following order: FimA-FimF-
FimG-FimH.51 Although not necessary for the expression of type 1 fimbriae, the latter 
was shown to be the responsible subunit for mannose-sensitive binding to bladder 
epithelial cells.52,53 Yet, type 1 fimbriae are not only the important mediator for 
adhesion, but also for subsequent cell entry, which was shown by Martinez et al. 
using latex beads coated with FimH to invade bladder cells via a zipper-like 
mechanism. Additionally, the invasion of FimH covered latex beads required 
reorganization of the actin skeleton, which was inhibited by the addition of D-
mannose. The PapG adhesin did not lead to bead or bacterial uptake into cells.54 
 
Interestingly, type 1 fimbriae are genetically encoded in uropathogenic isolates and 
fecal strains, but fim gene expression is regulated in a phase-variable manner.12 The 
gene expression for the fimbrial subunits can be switched “on” or “off”. This occurs 
via an invertible DNA element, which contains the promotor for the expression of the 
main subunit of type 1 fimbriae, the FimA. The inversion is mediated by FimB or 
FimE, both recombinases.19,55–57 FimB is able to switch from “on” to “off” and vice 
versa, whereas, FimE only switches to the “off” position.57 During experimental 
murine UTI, it was demonstrated that type 1 fimbriae expression was switched “on” 
in all bacteria from urine, bladder, and kidneys. On the other hand, only roughly 25% 
express type 1 fimbriae in in vitro broth cultures.56 The expression of FimB and 
FimE, ultimately controlling type 1 pili expression, are dependent on environmental 
growth factors. Low pH and high osmolarity favor the expression of FimE but repress 
expression of FimB, resulting in restricted expression of type 1 pili. These conditions 
are present in the human kidneys, whereas, in the bladder, the expression of type 1 
fimbriae is favored because of neutral pH and low osmolarity.57  
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Besides pH and osmolarity, also temperature, carbon and amino acid sources, 
availability of oxygen, and growth media can influence type 1 fimbriae 
expression.56,57 Of importance, glucose induces a cAMP-receptor protein (CRP) 
driven pathway leading to the inversion of fimB, resulting in type 1 fimbriae 
expression (Figure 1).58 In summary, the presence of the fim gene in the bacterial 
genome is a prerequisite, but the expression of type 1 pili is crucial for UTI. Mutants 
locked in the “off” position were outcompeted by the wild-type in a mouse model of 
UTI in all compartments; urine, bladder, and kidneys.59 
 
1.4. Cellular processes upon infection 
 
Uroplakin 1a (UP1a), the binding partner of type 1 pili, is part of a hexagonal 
complex called plaques. Plaques are built of four uroplakin subunits, UP1a, UP1b, 
UP2, and UP3a.20,60–63 They are important for flexibility, stability, and barrier function 
of the bladder and cover most of the luminal surface.20,60 Plaques are part of lipid 
rafts, which are membrane domains containing high contents of lipids and proteins, 
such as cholesterol, sphingolipids, and caveolin-1.61 Lipid rafts itself are membrane 
parts of fusiform vesicles. They undergo exocytosis when the bladder is stretched 
and are endocytosed when the bladder relaxes. This mechanism of membrane 
storage enables expansion and reduction of the bladder surface and is important to 
adapt to high stretching forces during urine accumulation.61,64,65 With UPEC binding 
to UP1a, the bacteria are internalized within the fusiform vesicles and enter luminal 
surface cells upon bladder emptying.66 Hence, UPEC employs a normal 
physiological mechanism for internalization, which is not only triggered by bladder 
extension and relaxation, but also via secondary messengers and complex signaling 
pathways.  
 
Within the tetramer of the uroplakin subunits, UP1a builds a heterodimer with UP3, 
which has a cytoplasmic domain and functions as a signal transducer.67 After binding 
of UPEC to UP1a, UP3 is phosphorylated at T244 by the casein kinase II (CK2), 
which leads to intracellular rising Ca2+ levels.67 This triggers several downstream 
effects, such as increasing cAMP levels, which in turn results in cytokine production 
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via activation of the transcription factor CREB, or in exocytosis of fusiform vesicles, 
both defense mechanisms against invading UPEC (Figure 1).62,64,66,67 
 
Eto et al. showed, that UPEC also binds to β1 and α3 integrins on the bladder cell 
surface. They proposed an alternative way of entering the bladder cell. Integrins 
contain high-mannose glycan structures similar to UP1a and appear in complexes.68 
The binding of UPEC to integrins leads to the autophosphorylation of FAK, which in 
turn triggers the PI-3 kinase and the activation of Rac1 Rho-family GTPase, involved 
in the modification of the actin skeleton of the cell. Actin rearrangement is necessary 
for endo- and exocytosis of fusiform vesicles.69  
 
Once inside the cell, UPEC start to replicate and form intracellular bacterial 
communities (IBC).65,66,70–72 
 
In the bladder, UPEC are also recognized by the immune system, via toll-like 
receptor 4 (TLR4) in complex with CD14. Thereby, TLR4 is a prominent receptor on 
bladder and kidney cells.20,65,66,73 It recognizes lipopolysaccharides (LPS) and type 1 
fimbriae and induces the transcription of IL-6 and IL-8, which attract neutrophils to 
the site of infection (Figure 1).66,67,74–77 UPEC counteracts with the secretion of 
cytotoxic necrotizing factor – 1 (CNF-1), interfering with neutrophil chemotaxis.66  
 
Another downstream effect of TLR4 stimulation, is the activation of the adenylyl 
cyclase 3 (AC3), again resulting in increased cAMP levels. As mentioned earlier, this 
provokes exocytosis of fusiform vesicles and simultaneously blocks their 
endocytosis. Thus, both GTPases, Rac-1, important for actin remodeling in lipid rafts 
to allow endocytosis, as well as Rab27, responsible for the delivery of fusiform 
vesicles to the apical surface of the bladder cells, are influenced by intracellular 
cAMP levels.60,61,63,64,66,74,78 
 
Of interest, Ashkar et al. argued that the FimH protein alone is the pathogen 
associated molecular pattern (PAMP) that initiates the TLR4 pathway. They could 
show, that cells and mice infected with purified FimH protein were up-regulating the 
immune response resulting in IFN-β production, requiring the Trif pathway besides 
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the MyD88 pathway (Figure 1). Remarkably, the induced immune response provided 
protection against a subsequent herpes simplex virus (HSV-2) infection in mice.79  
 
Furthermore, binding of FimH to UP1a leads to the activation of caspase 3 and 
subsequent apoptosis and exfoliation of infected bladder cells, which is an attempt of 
the immune system to eliminate infected cells.20,67 However, secreted CNF-1 and 
hemolysins (HlyA) also induce apoptosis via the same pathway (Figure 1), providing 
access to underlying immature bladder cells.66,80 Therefore, it is questionable, if cell 
shedding is advantageous or disadvantageous to clear the infection.  
 
Overall, UPEC developed an elegant way to survive the harsh conditions in the 
bladder. Besides employing a normal physiological process to enter the cells via 
fusiform vesicles, UPEC also secretes virulence factors, which modulate the immune 
responses. 
 
 
Figure 1. Synopsis of the mechanisms described for the cellular infection cycle and growth conditions for FimH 
expression.  
Introduction 
! 17 
1.5. The prototypic infection cycle 
 
The UTI cycle has been classified in early, middle and late IBCs (Figure 2).77,81 The 
early IBC stage is mainly characterized by the attachment and invasion of UPEC to 
and into bladder cells and occurs up to 3 hours post infection (hpi).82,83 In this stage, 
bacteria adapt a normal rod-shaped morphology and double approximately every 30 
minutes (Figure 2, 1. and 2.).77,81 Bladder cell invasion and formation of IBC 
represent a natural selection process for UPECs. An IBC is a clonal population 
arising from one individual bacterium, limiting genetic diversity for further infection 
stages (bottleneck).83 The time between 4-8 hpi, is termed middle IBC.81,84 Bacteria 
reduce their length and adapt a coccoid morphology with an estimated doubling time 
of more than one hour. An average IBC contains around 103-105 colony forming 
units (CFU).81,83,85 Middle IBCs have also been named pods, because of their visible 
extension into the bladder lumen.72 Starting at 12 hpi, bacterial pods burst and 
bacteria re-enter the bladder lumen for a new infection round (late IBC stage).81,82 
Bacteria change back from their coccoid shape to the normal rod-shape and regain 
motility.81 Many bacteria adapt a filamentous state during growth in IBCs, where they 
replicate without separation, growing as long as 70 µm. Upon fluxing, they divide and 
adapt their normal rod-shaped form.77,82,81,85,84 Most importantly, Andersen et al. 
could show that bacteria were able to restore their type 1 pili after escaping from 
cells and attach to further cells.85  
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Figure 2. UTI infection cycle showing the phases of the different infection stages. 1. Attachment of bacteria; 2. 
Invasion into the umbrella bladder cell; 3.-5. Early, middle, and late IBC; 6a. Cell burst and bacterial fluxing, 
which can lead to a new infection round. 6b. Cell shedding of infected cells, a defense mechanism of the host. 
Both, fluxing and cell shedding (6a and 6b) allow access to underlying immature bladder cells for the bacteria, 
leading to cell invasion (7) and the formation of quiescent intracellular reservoirs (8, QIRs). Approximate time 
span for the appropriate steps are indicated in red and apply to the first infection round.  
 
The intracellular replication is a fundamental process for the persistence of bacteria 
in the urinary tract. Bacteria invading, but lacking the ability to form IBCs, are rapidly 
cleared.86 By invading bladder cells, bacteria escape urinal voiding. Furthermore, 
within the intracellular biofilm-like state formed in an IBC, bacteria are protected from 
several immune measures. For example, granulocytes recruited to the infected cells 
cannot access bacteria, due to the protective effect of the biofilm polysaccharide 
matrix and the surrounding uroplakin shell.70,72 Moreover, granulocytes are not able 
to engulf filamentous bacteria.81 The importance of IBC formation is also shown by 
the fact that the genes for the establishment of an IBC are under positive 
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selection.86,87 Besides, IBCs as part of the uropathogenic infection cycle have been 
detected in cultured bladder cells, in mice, and in humans.71,88,89 Nonetheless, the 
high decrease of bacterial CFU within the first 12 hours of an infection is attributed to 
immune responses, such as neutrophil influx and cell shedding.82  
 
After apoptosis or bacterial outburst of superficial bladder cells, underlying immature 
basal and intermediate bladder cells become exposed to the infection.70,82 Yet, 
bacteria infecting these cells remain in a latent state and are not replicating. This so-
called quiescent intracellular reservoir (QIR, Figure 2, 8.) is often composed of only 
very few bacteria and remains undetected by the immune system, responsible for 
bacterial persistence. In mice, at 24 hpi, remaining bacteria in the bladder originate 
from IBCs, whereas, at 48 hpi, they originate from QIR.83 
 
Bacteria in immature cells are kept in a cellular compartment similar to a late 
endosome, which is tightly surrounded by actin filaments. Possibly, these filaments 
form a barrier for exchange of nutrients or growth factors from the cytosol to and 
from the endosomal compartment, which restricts bacterial growth. Eto et al. could 
show that as soon as the actin was destroyed, the bacteria started to replicate. They 
hypothesized that the progress from the QIR state into an active IBC state is 
triggered by the turnover rate of the bladder cells.90 During differentiation of 
immature cells into umbrella cells, changes in size, morphology, cytokeratin profile, 
and actin network, as well as the expression of UPs occur, enabling bacterial 
transition form QIR to IBC.91 The formation of QIRs together with maturation into 
IBCs upon cell differentiation would explain the frequently occurring recurrent 
infections after a specific time length.65,77,82,90,92 
 
1.6. UTI: Treatment standard and resistance rates 
 
Although UTI is a self-limiting disease, treatment of symptoms and decrease of 
disease burden is often necessary. The antimicrobial therapy of choice is most 
frequently, either trimethoprim/sulfamethoxazole (TMP/SMZ) or fluoroquinolones for 
three days, or β-lactams or nitrofurantoin for five days.93–97 
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Although a treatment for three days was shown to be less effective than a 5-10 days 
therapy, antibiotic intake should be minimized to reduce antibiotic resistance 
rates.98,99 Also, a single dose of fosfomycin parallels the effect of other treatment 
options in terms of microbiological and clinical success in uncomplicated UTI and is 
associated with low resistance rates.100,101 
Figure 3 is an overview about the mode of actions of the mentioned antibiotics. All 
exhibit a bactericidal or bacteriostatic effect, resulting in a selection pressure for 
bacterial survival.102,103 In contrast, targeting FimH does not exhibit such selective 
pressure, implying no or less occurrence of resistances. 
 
 
Figure 3. Schematic modes of action of antibiotics mostly used in the treatment of UTI.102,103 PABA: para-
aminobenzoic acid, DHF-A and THF-A: dihydrofolic acid and tetrahydrofolic acid, respectively. The mode of 
action of nitrofurantoin is not completely revealed, but it interferes with DNA replication and ribosomal 
translation.104,105 
 
Increasing resistance rates are a worldwide threat and include the majority of 
available antibiotics. Accordingly, resistant UTI pathogens were confirmed for 
several antibiotic classes like β-lactams, quinolones, aminoglycosides, and 
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tetracyclines and differ depending on countries and regions. For UTI treatment, only 
nitrofurantoin and fosfomycin lack high resistance rates so far.106,107 
 
Other possibilities for treating UTI are limited and include preventive options, such as 
increasing daily fluid uptake, changing hygiene procedures, or frequent urination. 
Also, the preventive intake of antibiotics is suggested in some cases.108,109 The latter 
is critical for the development of resistant strains, as a preventive intake of TMP/SMZ 
for one month results in resistant bacterial colonies in the intestine, which is a 
frequent source for uropathogenic bacteria.108 Also, a long-term prophylactic intake 
(daily, for approximately two years) of antibiotics in children at risk of rUTI showed 
that E. coli, the most common isolated uropathogen, developed a multidrug 
resistance in 55.5%, most often with cephalosporins and TMP/SMZ.110 Furthermore, 
it was revealed recently that subinhibitory concentrations of antibiotics, which result 
from low-dose preventive intakes, trigger the expression of adhesins, leading to an 
increase in biofilm formation and more extensive colonization of murine bladders of 
UPEC and Staphylococcus saprophyticus. Thus, recurrence was not prevented and 
infections were worse than the primary infection.111 
 
Another prominent preventive option is the intake of cranberry products. However, 
the usefulness is controversial. A meta-analysis by Jepson et al. reported no 
significant effect of cranberries compared to placebo groups in the occurrence of 
symptomatic UTI, neither in preventing rUTI.112 Contrarily, Wang et al. reported a 
positive correlation of cranberry product intake and the reduction of UTI 
incidences.113  
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1.7. Biofilm 
1.7.1. Biofilms in the face of UTI 
 
Costerton et al. described a biofilm as “matrix-enclosed bacterial populations 
adherent to each other and/or to surfaces or interfaces”.114 A microbial biofilm starts 
with attachment of individual bacterial cells with subsequent cell multiplication and 
production of extracellular polymeric substance (EPS).115,116 
 
Biofilms provide an advantageous way of growth for bacteria, offering protection from 
antimicrobial agents and the immune system of the host.117–123 Antibiotic tolerance 
increases by approximately 1000-fold when comparing planktonic bacteria with 
bacteria in biofilms.124 Consequently, biofilm-related infections are difficult to resolve 
by the host and also by antibiotic treatment.125,126 Thus, the ability for biofilm 
formation is considered as another important virulence factor for UTI. There, biofilms 
are not only important during IBC growth, but can also form on the surface of 
medical devices, such as catheters. 
 
1.7.2. Surface adhesion and biofilm formation – many factors involved 
 
The ability for biofilm formation depends on several factors. The most important 
factors described in literature, are discussed in Table 1. 
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Table 1. Overview of important proteins and structures involved in biofilm formation and promotion.  
Protein/Structure Role in biofilm formation 
Ty
pe
 1
 fi
m
br
ia
e 
Type 1 fimbriae mediate primary attachment to both, abiotic and biotic 
surfaces. They are required for aggregation and microcolony 
formation, a prelude for biofilm development.124,127–133 Type 1 fimbriae 
are up-regulated in biofilms and especially in CAUTIs or CAUTI 
mimicking conditions.37,134–137 The invertible DNA element responsible 
for the expression of type 1 fimbriae, is predominantly in the “on” 
position in strains isolated from catheterized patients.138 
Mutants deficient in type 1 pili expression have diminished biofilm 
formation capacities.129,133,138,139 Guiton et al. observed a 20-fold 
attenuation of biofilm of a FimH mutant strain on silicone tubing after 
24h.137  
C
ur
li 
Curli were first detected on the surface of E. coli and were described 
as coiled, thin auto-aggregative structures.140 They mediate initial 
surface adhesion and cell-to-cell contacts, because they only extend 
between 0.5-1 µm from the cell.14,141,130,142–144 Curli are important for 
the integrity of an initial pellicle formation, as they form a dense 
cellulose-containing network around the bacteria.133 They were shown 
to be vital for biofilm growth and in vivo fitness.145 
A
nt
ig
en
 4
3 
(A
g4
3)
 
The Ag43 is an autotransporter protein encoded by the flu gene, 
which is present in 83% of UPEC strains.14,39,146 It mediates auto-
aggregation through intracellular Ag43-Ag43 recognition and is 
important for biofilm formation on abiotic surfaces.39,130,14,146–150 Similar 
to type 1 fimbriae, also this adhesin shows a phase-variable 
expression.19 The presence of Ag43 was associated with long-term 
persistence in the urinary tract, since it was found in IBCs within 
bladder cells.39,72,141 
Fl
ag
el
la
 
Flagella are responsible for the movement in liquid environments and 
along surfaces. They allow deposition of bacteria at the right spot for 
the initiation of a biofilm.151,152 Although important for spreading and 
biofilm initiation, they are not required per se for adhesion and are 
absent in later biofilm stages.124,129,133,136,142 While it was reported that 
lacking flagella led to a defective biofilm formation, the catheter 
colonization ability of mutants lacking flagella compared to wild-type 
bacteria was not significantly different.129,138 
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Ty
pe
 3
 fi
m
br
ia
e 
Type 3 fimbriae were described for Klebsiella pneumonia and related 
to biofilm formation, both on catheters and other surfaces.37,38,141,153 
Type 3 fimbriae are encoded on a conjugative plasmid by the 
mrkABCDF operon and were transferred to many Enterobacteriaceae 
including UPEC.38,153 Similar to type 1 fimbriae, mutants defective of 
type 3 fimbriae show decreased biofilm formation.38 Type 1 and 3 
fimbriae were not detected in planktonic cells grown in urine, but are 
highly expressed in biofilms on catheters.37 Additionally, type 3 
fimbriae were not expressed when cultured in Luria-Bertani medium 
(LB).38 
E
P
S
 
The production of an EPS matrix is crucial for the establishment and 
development of a biofilm.154 The EPS consists of proteins, lipids, LPS, 
and bacterial DNA, but composition can vary between different 
species.116,124  
Even the EPS itself was proposed to be important for bacterial 
adhesion.155,156 Interestingly, also mannose is an essential part of the 
EPS.157,158 Rodriguez and Elimelech reported that upon addition of 1% 
of D-mannose to their growth medium, biofilm production was 
increased. Higher concentrations of D-mannose decreased the biofilm 
mass. They hypothesized that type 1 fimbriae are important for 
recognition of mannose and the build-up of the EPS.139 
 
In fact, the involvement of the factors described in Table 1 in biofilm formation might 
depend on the specific environmental conditions. For instance, many of the factors 
(type 1 pili, flagella, curli, and Ag43) are dispensable for an F plasmid promoted 
biofilm.115 Also, the list is not final and there might be more factors important for 
biofilm formation under specific conditions, for example F9 fimbriae.159 
 
During biofilm formation, the described adhesins and proteins act in a distinct 
interplay, depending on biofilm stage and environmental influences. For example, 
although expression of Ag43 is not inhibited by type 1 fimbriae, the latter is longer 
and hinders the Ag43 in mediating close cell-to-cell contact. Not only type 1 fimbriae 
can prevent Ag43-mediated aggregation, also flagella, LPS or capsule 
expression.149,160–163 Thus it was shown that upon deletion of the capsule gene, 
biofilm formation was greatly improved.38 Also, curli and flagella have an inverse 
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relationship concerning their expression.164,165 Similarly, type 1 fimbriae are not 
expressed when type 3 fimbriae are present, which is also true vice versa. Still, both 
types may be genetically encoded.37  
 
In summary, biofilms are the result of a distinct interplay of many factors and depend 
on environmental conditions, resulting in different morphological biofilm structures. 
 
1.7.3. Biofilms in catheter-associated UTI (CAUTI) 
 
Catheter-associated urinary tract infections (CAUTI) are a high health burden in 
hospitals and other health care institutions. In the United States, CAUTI is 
responsible for over one million cases yearly of nosocomial bacteriuria.166 In general 
hospitals, approximately 15-25% of patients have need for an urinary catheter during 
their hospital stay.167 CAUTI involves several bacterial species, such as 
Pseudomonas spp., Klebsiella spp., Staphylococcus epidermidis, Enterococcus 
faecalis, and Escherichia coli.168,169 The latter is responsible for approximately 30% 
of CAUTIs.170,171  
Silicone-latex catheters are prone for colonization and biofilm formation by UPEC.172 
Although strains causing asymptomatic bacteriuria (ABU) outcompete UPEC 
regarding their growth rate in urine, UPEC strains are better biofilm formers on 
silicone-latex Foley catheters.172–175 To prevent biofilm formation of uropathogenic 
bacteria on catheter surfaces, bacterial colonization is inhibited by coating with 
antibiotics or other antimicrobial agents. However, the effect lasts only for a short 
period of time.176–183 
Biofilm on a catheter surface, but also on drainage bags and in the uroepithelium 
itself, provide a constant source for bacteriuria. Therefore, the ability for biofilm 
formation characterizes strains causing rUTIs.167 
  
Introduction 
! 26 
1.8. The FimH anti-adhesive approach 
 
Already more than three decades ago, Aronson et al. proposed an anti-adhesive 
therapy targeting type 1 pili.47 However, it was only in 1997 when Langermann et al. 
proposed a FimH adhesin vaccination.184 Today, several studies using FimH 
antagonists as an anti-adhesive approach for the treatment of UTI have been 
published. An overview of the FimH antagonists proposed by different research 
groups and the obtained results are summarized in Figure 4 and Table 2. 
Introduction 
! 27 
 
Figure 4. Structures of FimH antagonists designed and tested by different research groups. 1, 2: Hultgren et 
al.137,185–187, 3, 4, 5: Ernst et al.188–190, 6, 7: Lindhorst et al.191,192, 8: Boukaert et al.193, 9: Roy et al.194  
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Table 2: Results of 1-9 reported by the corresponding research groups. 
Group and 
antagonist 
number 
Summary of published results Ref 
Hultgren et al.  
 
Antagonists 1 & 2 
Biphenyl-mannopyranoside derivatives showed improved 
activity in in vitro hemagglutination and biofilm assays 
combined with good pharmacokinetic (PK) properties in vivo. 
With modifications on the biaryl structure, the previous lead 
structure could be improved, increasing its’ potency by 
approximately 5-fold and showing higher overall plasma and 
urine concentrations (1).  
185 
An orally available FimH antagonist (1) was effective in the 
murine model of UTI. Furthermore, the potential of FimH 
antagonists in preventing acute UTI and treating chronic UTI 
(Log10 3 CFU/ml reduction in the bladder) caused by a 
multidrug-resistant E. coli strain was shown. Also, the study 
provided insight into the long-term pathogenic mechanisms in 
the bladder. 
186,187 
An orally applied mannoside (2) prevented a CAUTI infection in 
mice and potentiated the effect of TMP/SMZ. 
137 
Ernst et al. 
 
Antagonists 3-5 
Orally available FimH antagonists were successfully applied in 
vitro and in vivo. Various studies explored different aglycones. 
The best antagonists were applied intravenously (i.v., 3) and 
orally (p.o., 4 & 5) and reached a reduction of Log10 3 CFU/ml 
in the bladder of the UTI mouse model. With a bioisosteric 
replacement of the carboxylate in the para-position of the outer 
aromatic ring of the biphenyl aglycone with cyanide, the PK 
properties of 4 were markedly improved (5). 
188–190 
!! !
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Lindhorst et al. 
 
Antagonists 6 & 7 
The group investigated the inhibition of binding of type 1-
fimbriated E. coli to mannoside- and mannan-coated surfaces 
by squaric acid monoamide mannosides (6). Docking studies 
revealed a specific binding of the glycon moiety to the 
carbohydrate recognition domain (CRD) of FimH, with the 
aglycon moiety interacting with the entrance of the FimH CRD. 
191 
Photoswitchable azobenzene mannobiosides (7) showed 
promising binding to the FimH CRD in silico. This could be 
useful in developing photoswitchable adhesive surfaces for 
glycoarrays. 
192 
Bouckaert et al. 
 
Antagonist 8 
Mono- and heptavalent gylcoconjugates connected to β-
cyclodextrin were tested as FimH antagonists in the mouse 
model of UTI. Instilling 2 µg of the heptavalent antagonist 
together with bacteria directly into the bladder of mice led to a 
decrease of the CFU of approximately 1 to 2 Log10 units. 
Furthermore, the glycoconjugates were shown to rapidly reach 
the mouse bladder upon intravenous application and retaining 
urine levels over 2 µg for 24 hours. 
193 
Roy et al.  
Antagonist 9 
Mannosylated dendrimers were tested in the hemagglutination 
assay. A 500-fold increase in potency compared to methyl α-D-
mannopyranoside was achieved.  
194 
 
1.9. FimH shows a catch bond behavior 
 
The FimH of UPEC has different natural variants exhibiting different binding 
characteristics. Mutations in the FimH gene are pathoadaptive, i.e., they provide an 
advantage for uropathogenic isolates in colonizing the urinary tract compared to their 
fecal relatives.195,196 Fecal strains show very low adhesion capacities to 
mannosylated surface structures opposed to uropathogenic strains.195 However, not 
all UPEC isolates show the same binding pattern. Some are able to adhere to 
monomannosylated structures, whereas most of the strains are only able to bind 
trimannosylated structures. Yet, the binding of monomannosylated structures 
correlates with the binding to uroepithelial cells.197–199 
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The lectin FimH at the tip of type 1 fimbriae is composed of an N-terminal lectin 
domain, containing the CRD, and the C-terminal pilin domain (Figure 5), connecting 
the FimH to the other subunits of the type 1 fimbriae (FimG, FimF, and the multiple 
subunits FimA anchored into the cell membrane).200,201 Upon spatial separation of 
the lectin and pilin domains, the affinity of the CRD to mannose is strongly 
enhanced, due to a β-sheet twist in the lectin domain, leading to a tighter binding 
pocket (Figure 5, green loop). This is the case either in the natural course of 
infection, where urine flow leads to a shear induced separation, or when the FimH 
has a structural mutation leading to a constant separation of both domains. The 
strengthening of binding upon domain separation due to shear force is called a 
catch-bond mechanism.198,201–204 Thus, the pilin domain functions as an allosteric 
inhibitor of mannose binding of the lectin domain. Furthermore, it was proposed that 
the binding of a ligand in the lectin domain in some strains mediates a change from 
the native, low affinity form of FimH to a medium affinity binding with slightly superior 
affinity, which is further enhanced upon complete domain separations induced by 
shear force (high affinity state).199,201  
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Figure 5. High and low affinity states of FimH and the differences in the overall structure of the two domains. For 
the high affinity state (red), the protein was crystallized with the FimC chaperone, interrupting the interaction of 
both domains. The β-sheet twist leads to the closing of the binding pocket (indicated in green) and enhanced 
binding of mannose. The structures were created with PyMol Software by Deniz Eris (PDB codes: 1QUN and 
3JWN). 
 
The differences in binding strength to monomannosylated structures of different 
UPEC can be explained by different mutations in the fim gene. Although 90% of the 
amino acids in the FimH structure are conserved in UPEC strains, a few can 
influence the conformations of the lectin domain, or the interaction between the lectin 
and pilin domain.86 Systematical analyses of mutational changes within different 
structural regions of the lectin domain and in the inter-domain region revealed the 
influences upon the affinity state of the binding pocket towards mannose. By 
expressing different residual mutations in an E. coli K-12 background, it was shown 
that several regions within the two domains are important in the allosteric switch from 
low to high affinity.199 Importantly, different combinations of amino acids at positions 
27, 62, and 163 were implied to increase or decrease virulence in the murine mouse 
model by influencing the affinity state of the FimH.86,205  
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Overall, the FimH protein represents an elaborate catch-bond mechanism system, 
providing a dynamic attachment of UPEC to the bladder epithelium. The concept of 
the different binding states of FimH is schematically displayed in Figure 6. It is 
important to consider not only two different states, but include the intermediate state, 
induced by ligand binding. 
 
 
Figure 6. Schematic representation of the different affinity states (low-medium-high) of FimH towards ligand 
binding. 
 
Soluble FimH antagonists are not able to benefit from shear force enhanced binding, 
but compete with a ligand that does (UP1a, fixed on bladder cell surface). Therefore, 
antagonists should target the low and intermediate state FimH to completely abolish 
binding to bladder epithelial cells. 
 
1.10. Summary and Outlook 
 
Because of a very high prevalence as well as increasing resistance rates, there is an 
urgent need for new therapeutic options to treat UTI. However, since the infection 
cycle is the result of a complex bacterial and cellular interplay and frequent rUTI are 
common, it is a challenging task. Nevertheless, blocking FimH has shown promising 
results so far. This therapy could proof successful in preventing rUTI and could 
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possibly replace an antibiotic prophylaxis also in CAUTI. Likewise, it could reduce 
the use of antibiotics in UTI therapy, by applying FimH antagonists in combination. 
Consequently, it could help to delay resistance development of frequently used 
antibiotics against UTI. 
 
FimH antagonists do not directly exert a selection pressure for bacterial survival and 
the receptors on bladder cells are also unlikely to evolutionarily change their 
mannosylated surface. Therefore, resistance development against FimH antagonists 
is doubtful, since this would require a mutational change in the FimH CRD, which 
would also abolish binding to natural receptors. Yet, it could be that the bacteria 
employ other adhesins suitable for establishing contact with the host cell and 
initiating infection.  
 
In a wider perspective, not only the therapy for UTI could profit from an anti-adhesive 
approach. Many bacteria and viruses use a carbohydrate binding-epitope for 
adhesion and initiation of infection. Therefore, glycomimetics could become a new 
class of therapeutics to treat infectious diseases.206  
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In the past few years, FimH antagonists showed promising results in several in vitro 
and in vivo assays (see Table 2), were successfully used against chronic cystitis in 
mice, and were applied against CAUTI in a mouse model.137,187 However, nor the 
appropriate PK/PD index for the application of FimH antagonists, neither an optimal 
application regimen was yet established.  
 
The aim of this thesis was to assess treatment applications of FimH antagonists in 
the context of the complex infection cycle of UTI. Therefore, preventive and 
therapeutic applications were studied in different set-ups. Variations included 
treatment time, inoculum, time of infection, and application routes. Moreover, the 
potency of FimH antagonists for the prevention of biofilm formation in relation to 
CAUTI was investigated. Overall, this thesis aimed at guiding treatment regimens for 
future applications in patients. 
 
Besides, within different optimization projects, newly synthesized antagonists were 
characterized for their PK and pharmacodynamic (PD) performance in vitro and in 
vivo. 
 
Furthermore, the influence of the FimH affinity states of different UPECs upon 
antagonist binding was investigated. Yet, further studies are needed, as this will be 
an important and inevitable step towards general treatment finding.  
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This section shortly discusses the most important methods used for the results 
gained in this thesis. Thereby, the focus lies on reporting of advantages and 
disadvantages of assay systems regarding the interpretation of their outcome, rather 
than reporting detailed assay protocols. However, protocols that are no part of a 
manuscript or paper, but results are shown in this thesis (microscopy and PCR), are 
also described here in detail. 
 
3.1. Bacterial cultivation 
 
Generally, bacteria were cultivated in type 1 pili inducing conditions, i.e., in 10 ml LB 
medium, static, at 37°C for the designated time length important for the assays.82 
The expression of type 1 pili under these conditions was confirmed with fluorescence 
microscopy (Figure 7A). 
 
3.2. In vitro cell infection assay 
 
The in vitro cell infection assay was performed as previously described, however 
with some modifications.207 The assay was used to determine the minimal anti-
adhesive concentrations (MAC90) of several antagonists and different UPEC strains.  
 
The detailed assay procedures were published in PAPER I. In general, cells were 
infected with green fluorescent protein (GFP) expressing bacteria and incubated for 
1.5 h (or indicated time lengths). Then, cells were washed to remove non-attached 
bacteria, detached from wells and analyzed using flow cytometry. Living cells were 
gated selectively via side scatter (SSC) and forward scatter (FSC), and analyzed for 
their GFP intensity. This reflects the amount of bacteria either binding to or 
internalized into the individual cells (Figure 7).  
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Figure 7. (A) GFP-expressing J96 with stained type 1 pili (Alexa 647, red), which proofs the expression of type 1 
pili on the surface of J96 bacteria. (B) 5637 bladder cell after three hours of infection with J96. The cell nucleus 
(blue, DAPI) and the F-actin skeleton are labeled (orange, rhodamine-phalloidin). Bacteria cluster on the cell 
surface, partly within the cell. The red stain of type 1 pili is only weakly visible. (A) and (B) were pictured with 
fluorescence microscopy at 100X and 60X magnification, respectively. Bars represent 10 µm. (C) Schematic 
explanation of the in vitro cell infection assay. Cells were infected with UPEC and incubated at 37°C (1. and 2.). 
After incubation, cells were washed to remove non-adherent bacteria (3.). After cell transfer from wells into tubes, 
living cells were gated within flow cytometry and analyzed for their GFP intensity (4.-6.)  
 
The human bladder carcinoma cell line 5637 is widely used for the assessment of 
pathogenicity of UPEC strains and infection cycle studies.54,61,64,68,208,209 They show 
typical characteristics of the in vivo infection, such as bacterial attachment, invasion, 
and fluxing.54,82 Also, they express UP1a, integrin receptors, as well as TLR4, and 
type 1 pili provoke a cytokine response. 61,68,74,210 Therefore, the 5637 cell line offers 
a good model for the screening of antagonists, most closely mimicking in vivo 
infection events. Yet, the assay is very delicate. Within the master thesis of Nathalie 
Lüdin and Rachel Zimmermann, the assay was optimized in several respects. First, 
the bacterial load for infection was reduced to optimize the multiplicity of infection 
(MOI). This is an indication for the ratio of bacteria per cell. Second, the assay 
procedure was refined, e.g., cells were detached using trypsin (Invitrogen) and 
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dissolved in phosphate buffered saline (PBS) containing 2% fetal calf serum (FCS, 
Invitrogen) to increase the number of living cells. Third, to reduce cell clumping, the 
samples were filtered before measurement to eliminate false negative exclusions 
while gating for living single cells. Also, the analysis within the flow cytometer was 
refined, i.e., to accept a result, minimally 10’000 living cells had to be recorded and 
cell viability was related to all measured events. The viability should be minimally 
20% for valuable sample analysis.  
 
Despite these refinements and optimizations, the assay system remains sensitive. 
Although the number of seeded cells per well was constant, after two days of growth, 
it varied between 5 x 104 and 3 x 105. The bacterial numbers ranged from 2 x 107 to 
1.7 x 108 CFU/well. This results in MOIs from 400 to 3400, a factor of 8.5. 
Furthermore, Rachel Zimmermann found that the amount of pili expressed by 
different UPECs using immunostaining varied considerably. Also, the GFP intensity 
of the individual strains was different, although they harbor the same plasmid and 
were grown in the same culture conditions. During the assay, which is quite labor 
intensive, the time frame used for specific steps also influences cell viability and 
ultimately the assay outcome. These reasons are most likely responsible for the 
variability of the assay results.  
 
Moreover, a crucial point of the natural infection cycle is the detachment of umbrella 
bladder cells, either by natural immune reactions or by bursting after extensive 
intracellular replication of bacteria. This renders the underlying immature cells 
exposed to the bacteria.20,66,67,80 Yet, this effect cannot be studied with the present in 
vitro model, as the cells grow in a monolayer and lack multi-dimensions. Therefore, 
they are only representative for the initial infection events, such as attachment and 
invasion. Therefore, the 3D-organoid bladder model, as presented by Smith et al. 
would be promising to study the whole infection cycle of UTI in vitro.209 
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3.3. The C3H/HeN mouse strain for PK studies and infection 
 
The exact procedures for PK studies and infection studies are described in 
PAPER I/PAPER II/PAPER III/ MANUSCRIPT I. The different treatment schemes 
are discussed in Chapter 4.3.1 and MANUSCRIPT I. 
 
The mouse model of ascending UTI was originally described by Hagberg et al. and is 
an established model for studying antibiotic treatment regimens in UTI.48,211 The 
mouse model offers several advantages. Mice express the Gal(α1-4)Galβ glycolipid 
binding-motif for kidney infections, which is also expressed in humans, but not in 
rats.48,212 In parallel to human infections, mice are infected via the ascending, 
transurethral route and are able to clear the urine of bacteria without treatment after 
some time.211 Furthermore, mice also show IBCs, similar to the human 
pathogenesis.71  
 
On the other hand, Lanne et al. argued that C3H/HeN mice show different 
isoreceptor patterns regarding glycolipids and glycoproteins in the urinary tract 
compared to human or monkey.213 Also, C3H are susceptible to vesicourethral reflux 
(VUR), allowing fast kidney infections.214 Since VUR is critical for the assessment of 
kidney infections, transurethral inoculation was performed carefully, injecting 50 µl 
over a time-span of 30s with a Hamilton syringe.215 However, this does not 
completely rule out the possibility of VUR.216,217 Although the activity of FimH 
antagonists is focused on bladder infections, one should consider these facts 
analyzing kidney infections.  
 
3.4. Biofilm 
 
The classical biofilm assay using crystal violet (CV) staining was first described by 
Christensen et al. and was later modified in several studies.218 Most prominent were 
the modifications by O’Toole et al., which served as the basic protocol for the studies 
in this thesis.219 The detailed assay procedures employed for this work are described 
in MANUSCRIPT II. 
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Crystal violet is basic and binds to extracellular, negatively charged molecules on the 
cell surface or in the polysaccharide matrix of biofilms.220 In general, the assay is 
easy to perform, widely used, cheap, and delivers reproducible results in most 
cases.221 
Nonetheless, CV-staining is not suited for distinguishing living from dead cells and 
strongly depends on washing steps within the assay, which makes it difficult to 
compare results between laboratories or even between individuals.221,222 Therefore, 
CV assays should be used for a general screening, but must be accompanied by 
enumeration of bacteria for detailed information about the amount of living bacteria 
within a biofilm. 
 
The assay format used for the testing of biofilm on a catheter surface, as presented 
in MANUSCRIPT II, offers a reproducible and robust method to test strains, catheter 
material, and therapeutics. It allows a simultaneous screening of different conditions 
in a 96-well plate and is only moderately time consuming. 
 
3.5. Microscopy 
 
Microscopic experiments were performed aiming at revealing cell infection 
processes, morphological changes of bacteria (i.e., pili expression, bacterial form), 
and analysis of biofilm structures. Ultimately, visualization should help to assess type 
1 pili expression within the infection cycle and might determine treatment possibilities 
with FimH antagonists. 
 
Pictures of the cell infection assay and of the biofilm were obtained by fluorescence 
microscopy, which included the following steps:  
Cells or biofilms were cultured on 8-well µ-slides (ibidi, Germany). For the staining of 
bacterial type 1 pili, 200 µl of a highly concentrated bacterial solution from a washed 
overnight culture (optical density (OD600) of 2) was mixed with 100 µl of an anti-type 
1-pili rabbit antibody (1:250 in 2% bovine serum albumin (BSA) in PBS, kindly 
provided by Dr. Carsten Struve and Prof. Karen Krogfelt, Statens Serum Institut, 
Denmark) and incubated for 30 min at room temperature, before centrifugation 
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(13000 rounds per minute (rpm) for 1 min) and washing of the bacterial pellet (3x in 
PBS). Then, the pellet was dissolved in 100 µl of the secondary antibody, Alexa 647 
chicken anti-rabbit IgG (Invitrogen) and incubated for 30 min at room temperature. 
After a further centrifugation and washing step, the bacterial pellet was dissolved to 
the desired OD600 and used for the assay.  
 
For staining, cells or biofilms were washed two times with PBS at room temperature 
before fixation with paraformaldehyde (3.7%, Sigma-Aldrich) for 5 min at 37°C. After 
fixation, wells were washed with PBS and 200 µl Triton 0.1% (Sigma-Aldrich, in 
PBS) were added for overall 10 minutes at 37°C. Thereby, the Triton solution was 
exchanged after 5 min incubation. After washing, a 5% BSA (Sigma-Aldrich) solution 
was added for 1h. Following removal of BSA and washing with PBS (2x), rhodamine-
phalloidin 1U (Invitrogen) was added at room temperature for 20 min. Anew washing 
with TBS Triton 0.1% (3x) followed before staining with DAPI (Sigma-Aldrich) for 
another 5 min. After washing of the DAPI solution with Tris-buffered saline (TBS, 1x), 
mounting media (Vectashield H1000) was added to protect fluorescence before wells 
were sealed with the coverslip. For picture caption and analysis, the widefield Delta 
Vision Core System and the SoftWorx software at the Imaging Core Facility of the 
University of Basel was used. Images were prepared with Imaris x64. 
 
3.6. PCR of FimH 
 
For PCR of the lectin domain of FimH from different UPECs, the bacteria were 
cultured overnight and DNA was purified using the Wizard® Genomic DNA 
Purification Kit. Then, PCR was performed adding dNTP mix (Sigma Aldrich), 
Polymerase (iProof, BioRad) and the following primers: FimH seq Fwd, 
ACCGCGCAAAACATCCAGTT and FimH seq rev, CCGGTGGCGCTTTATTTG 
(Microsynth). After PCR (BioRad iCycler®), the products were analyzed in a 1.25% 
agarose gel (Sigma Aldrich) with electrophoresis. To purify DNA, the Gen Elute PCR 
Glean up Kit (Sigma Aldrich) was used. Sequenzing of purified DNA was done by 
Microsynth AG, Switzerland. 
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The following sub-chapters summarize the central investigations and achievements 
of this thesis. They are grouped into main project areas and are more or less 
extensive, depending on the focus of this thesis. Publications and manuscripts 
resulting from these projects are indicated and numbered within the text and are 
included in chapter 5.  
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4.1. Optimization of pharmacokinetic and pharmacodynamic 
properties (PAPER I and PAPER II) !
PAPER I !
As mentioned in chapter 1.8 „The FimH anti-adhesive approach“, numerous 
antagonists have been published over the last few years. However, to reach 
therapeutic efficacy, high doses were needed, mainly because of insufficient PK 
properties. Therefore, starting from a biphenyl α-D-mannopyranoside, new 
antagonists were synthesized using a bioisosteric replacement strategy, striving 
towards higher oral bioavailability and renal excretion, while maintaining the high 
pharmacodynamic activity of the antagonists. The results were published in PAPER 
I: !
„FimH Antagonists: Bioisosteres To Improve the in Vitro and in Vivo PK/PD Profile“!
 
Simon Kleeb,# Lijuan Pang,# Katharina Mayer,# Deniz Eris,# Anja Sigl,# Roland C. 
Preston, Pascal Zihlmann, Timothy Sharpe, Roman P. Jakob, Daniela Abgottspon, 
Aline S. Hutter, Meike Scharenberg, Xiaohua Jiang, Giulio Navarra, Said Rabbani, 
Martin Smiesko, Nathalie Lüdin, Jacqueline Bezençon, Oliver Schwardt, Timm Maier, 
Beat Ernst 
# equally contributed 
 
Journal of Medicinal Chemistry, February 2015 
 
My contributions: 
• Conducting some of the PK studies and their evaluations, as well as all 
infection studies and their analysis.  
• Taking part in project discussions, manuscript preparations, and in the review 
process. 
  
Results and Discussion 
! 46 
!
PAPER II 
 
In another project, previously tested ester-prodrugs of biphenyl α-D-
mannopyranosides were synthesized in order to increase oral bioavailability resulting 
from an increased permeation in the gut. However, by this modification, solubility 
decreased dramatically. Disrupting the molecular planarity and symmetry of the 
biphenyl aglycone increased solubility and at the same time retained high 
permeability. This was achieved by introducing heteroatoms in the outer aromatic 
ring of the biphenyl aglycone. Also, the molecules of this new series proofed to be 
metabolically stable and were excreted unchanged. One of the antagonists resulted 
in urine concentrations over 1 µg/ml for 6 hours after oral application. The results are 
reported in PAPER II: 
 
“FimH Antagonists – solubility vs. permeability” 
 
Lijuan Pang,# Jacqueline Bezençon#, Simon Kleeb#, Said Rabbani, Anja Sigl, Martin 
Smiesko, Christoph P. Sager, Oliver Schwardt, and Beat Ernst* 
 
# equally contributed 
 
Journal of Carbohydrate Chemistry, October 2016 
 
My contributions: 
• Performing the in vivo PK study and providing the according text for the 
manuscript. 
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4.2. Optimization of oral bioavailability via prodrug approach 
(PAPER III) !
PAPER III 
 
The most practical and simplest way for drug application for patients suffering from 
UTI, is via the oral route, which would also allow for easy frequent dosing. Therefore, 
the ideal FimH antagonist should be orally available. Although several mannosides 
were identified with high affinities, promising a good therapeutic effect, many suffer 
from low solubility. This restricts oral availability not only by limiting the maximally 
applicable dose in a given volume, but also by limiting drug dissolution within the 
intestines, a prerequisite for permeation. Therefore, the oral bioavailability of FimH 
antagonists belonging to the biopharmaceutical classification system (BCS) class II 
(low solubility, high permeability), could be markedly improved if intestinal fluids were 
saturated and high doses could be applied.223 A prodrug approach was studied to 
increase solubility of potent FimH antagonists. Inspired by marketed drugs, such as 
Fosamprenavir, phosphate prodrugs were synthesized and analyzed regarding their 
PK parameters in vitro and in vivo.224,225 The results are presented in PAPER III: 
 
“FimH Antagonists - Phosphate Prodrugs Improve Oral Bioavailability” 
 
Simon Kleeb,# Xiaohua Jiang,# Priska Frei,# Anja Sigl, Jacqueline Bezençon, Karen 
Bamberger, Oliver Schwardt, and Beat Ernst* 
 
# equally contributed 
 
Journal of Medicinal Chemistry, March 2016 
 
My contributions: 
• Performing and evaluating all in vivo PK studies and discussing results for 
further development 
• Providing the text for the in vivo part and assisting in editing part of the text. ! !
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4.3. Application of FimH antagonists in UTI and CAUTI 
4.3.1. Finding the optimal treatment regimen for UTI (MANUSCRIPT I) !
MANUSCRIPT I 
 
Anti-adhesive therapies pose a new challenge regarding an optimal treatment 
regimen. The basis for a successful anti-adhesive therapy is the exactly timed and 
dosed application in regard of the natural infection events. The different stages of the 
infection described in chapter 1.5., would suggest a preventive application, i.e., 
before bacteria attach to bladder cells, or after fluxing, when re-expressing type 1 
fimbriae. The attempts for conventional PK/PD index finding, as it is performed in 
other areas, failed, most likely because of a missing preventive dose (internal data). 
Therefore, treatment finding started from the basic assessment of a preventive 
application, using the reference n-heptyl α-D-mannopyranoside (1, Figure 10). 
Thereafter, three antagonists from the internal collection were chosen based upon 
their in vitro minimal anti-adhesive concentration (MAC90) and PK results. The most 
promising candidate was selected to study the long-term preventive effect of a single-
dose, (see MANUSCRIPT I). The basic workflow and the antagonist structures are 
shown in Figure 8 and Figure 10, respectively. 
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Figure 8. Basic workflow for the identification of the optimal application of FimH antagonists in UTI infection. Blue 
rectangles show the performed studies, red rectangles display the reasoning for the studies. The antagonist 
structures are displayed in Figure 10. !
4.3.1.1. Pre-assessment of treatment/prevention possibilities 
 
For all infection studies, the previously used and established murine infection model 
was used.48,188,211,226 For the validation of antagonists, a short-term infection (up to 3 
hours) was employed as described in previous publications from our group.188–190 
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The model is valuable to determine the potency of inhibiting the initial attachment and 
reducing the acute bladder infection. In a first step, different time points of addition of 
the antagonist relative to the infection time was studied. This should explain the 
importance of the timing of antagonist application and its availability within the short-
term infection, which mainly includes attachment and invasion. The reference 1 was 
applied intravenously at a dose of 20 mg/kg at four different times (Figure 9). The 
effect of 1 is clearly most potent in a preventive application, as shown by the 1-3 
Log10 reduction in all compartments after a preventive application (-30 min and -
15 min). Most prominent is the bacterial reduction in the bladder of group 1 (-30 min).  !
!
Figure 9. Log10 CFU/ml compared to the untreated control group (zero level line) depending on treatment time 
relative to infection. Bars represent mean Log10 reduction of treated groups compared to the mean Log10 of 
controls with SD in urine, bladder, and kidneys (n=4, control values of 6 mice). 
 
The later the antagonist was applied (group 1 to 4) the higher the recovered bacterial 
burden. First, urine counts increased upon later treatment, then bladder counts, 
whereas the kidney counts showed an opposite trend. There was a reduction in the 
kidney counts even when the antagonist was added 40 min after infection, but there 
was no effect when applied later. The increasing bacterial counts with time may be 
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explained by the ascending nature of the infection. To avoid attachment to bladder 
cells, the antagonist must rapidly reach a high concentration in urine. Application of 
antagonist at a later time point showed therefore a lower effect, reflected in the 
increasing bladder counts. The infection in the kidneys is a slower process, as 
bacteria need time to ascend from the bladder. This explains the prolonged effect of 
antagonist in the kidneys compared to the effect in the bladder or urine, even when 
antagonist 1 was added after the infection. 
 
Overall, the time point of antagonist addition is crucial for the development of the 
infection and depends on antagonist availability in urine, i.e., the PK characteristics of 
the individual antagonists. Clearly, FimH antagonists have the highest effect upon a 
preventive application in acute bladder infection.  !
4.3.1.2. Compound selection !
Three FimH antagonists were selected for comparison of potency upon a preventive 
application in the acute bladder infection mouse model. For a future application in 
patients, antagonists should be orally available. Therefore, testing was performed by 
oral application only and high solubility and reasonable permeability were preliminary 
criteria. The selected antagonists represent two distinct chemical classes, the 
indolinylphenyl mannopyranoside derivatives, 2188 and 3, and the biphenyl 
mannopyranoside derivatives 4190 (Figure 10).  
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Figure 10. The reference n-heptyl α-D-mannopyranoside (1), two indolinylphenyl-mannopyranoside derivatives (2 
& 3), and a biphenyl mannopyranoside derivative (4) were chosen for the evaluation of their effect in a murine UTI 
infection model. The phosphate-prodrug 2, with a phosphate in position 6 of the mannose moiety was used to 
increase solubility (PAPER III). 
For an appropriate treatment regimen, a minimal local concentration of a FimH 
antagonist in the bladder is required. Similar to the minimal inhibitory concentration 
(MIC) used as reference level for activity of antibiotics, the minimal anti-adhesive 
concentration (MAC90) was defined, representing the minimal therapeutic 
concentration in urine required to inhibit 90% of bacterial adhesion. It is measured 
using in vitro bladder cell cultures and evaluated by flow cytometry (chapter 
3.2.).188,207 
Antagonist 2 is a potent FimH antagonist, which showed a three Log10 units  
reduction in bladder infection counts upon intravenous administration in the murine 
infection model (48a from Jiang et al.).188 Since antagonist 2 has very low intrinsic 
water solubility (24 µg/ml), it was not suitable for oral application. A prodrug strategy 
using phosphate derivatives for improving water solubility (PAPER III) was effective 
in increasing solubility over 3000 µg/ml. Yet, 2 resulted in a MAC90 value of 0.5 
µg/ml.188 
Antagonist 3 was selected because of higher intrinsic water solubility (>250 µg/ml), 
and best membrane permeability within this series (PAMPA Log Pe -4.6 cm/s, 
measured by Jacqueline Bezençon), although it showed lower activity in the cell 
infection assay (MAC90 11.18 µg/ml).207 Antagonist 4, representing the biphenyl 
mannopysanoside derivatives, was chosen because of acceptable water solubility 
O
HO
HO
O
O O
P
OH
OHHO
O
N
NO2
O
HO
HO
O
OH
OH
CN
Cl
2 3 4
O
HO
HO
O
HO
OH
N
Cl
H3CO
O
HO
HO
O
HO
OH
1
Results and Discussion 
! 53 
(192 µg/ml, Jacqueline Bezençon) and high activity in the cell infection assay (MAC90 
0.09 µg/ml).190 
 
To investigate the significance of the MAC90 as a guideline for an effective 
therapeutic concentration and establishment of an appropriate treatment regimen, 
the MAC90 was evaluated in the context of the PK of the individual antagonists.!!!
4.3.1.3. In vivo pharmacokinetic studies !
The three FimH antagonists were orally applied, each to three mice, and urine 
concentrations were measured over time (Figure 11). Antagonist 3 was investigated 
twice, with a dose of 1.25 mg/kg, based on solubility, and 10 mg/kg, resulting of the 
improved solubility when formulated with 5% DMSO and 1% Tween 80 in PBS (see 
PAPER I).190 !
 
Figure 11. Urine levels of 2, 3 and 4 over time after oral application. The MAC90 levels are indicated by a dashed 
line and colored according to the corresponding antagonist. The doses were: 2 (blue): 10 mg/kg, 3 (red): 5 mg/kg, 
4 (black): 1.25 mg/kg and 10 mg/kg.  !
Generally, all three antagonists showed prolonged concentrations above 0.5 µg/ml in 
urine starting from approximately 30 min after application and extending up to 
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8 hours after application. The antagonists accumulated in urine and led to high urine 
levels, which was considered beneficial for antagonizing bacterial attachment in the 
bladder. The indolinylphenyl derivative 2 showed a fast increase in urine levels within 
the first few minutes, but reached the Cmax of 4.5 µg/ml at 3 hours post application 
resulting in a Cmax/MAC90 ratio of circa 9. The overall T>MAC90 was approximately 6 
hours (2 to 8 hours after application). 
 
For antagonist 3, urine levels also maximized between 1.5 and 2 hours post 
application (7.4 µg/ml) and slowly decreased to 2.3 µg/ml after eight hours. Despite 
the high intrinsic solubility, the best permeation results in the PAMPA assay, and the 
highest urine levels in the mouse, the MAC90 was never reached. Therefore, it will 
probably only have minor effects in an infection treatment.  
 
FimH antagonist 4 also showed an accumulation in urine for both dosages 
(1.25 mg/kg and 10 mg/kg). Both curves parallel nicely, yet, the dose increase of a 
factor eight (from 1.25 mg/kg to 10 mg/kg) increased the Cmax from 3.3 µg/ml (1.5h) 
for the low dose to 112.6 µg/ml for the high dose (0.5h), which is a factor of 
approximately 37. This indicates that the formulation effectively increased drug levels 
in urine, not only because of an improvement of solubility, but also because of the 
inhibition of efflux transporters in the intestines by Tween 80.227,228 Both doses result 
in urine levels of roughly 2 µg/ml at 8 hours after application. The T>MAC90 for 
antagonist 4 with 10 mg/kg and 1.25 mg/kg was 24 hours, corresponding to 100% of 
the time measured. Therefore, although the formulation increased the Cmax of 
antagonist 4, it did not markedly prolong the T>MAC90. The Cmax/MAC90 ratio was 
approximately 30 for the low and over 1000 for the higher dosage. 
 
In a next step, the three antagonists were applied in the acute bladder infection 
model (3 hours infection) to test the validity of combining the previously determined 
MAC90 value with the PK study results for an effect prediction. All antagonists were 
preventively applied. 
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4.3.1.4. Acute bladder infection inhibition potential 
 
The short infection time of 3 hours allows to study initial adhesion and invasion 
starting immediately after bacteria (experimentally) entered the bladder.81 The 
antagonists were orally applied 40 min before infection with the bacterial strain 
UTI89. This guarantees that the experimental infection is initiated when high 
antagonist concentrations in urine are available. Based on the pre-assessments 
(T>MAC90 and/or Cmax/MAC90), antagonist 3 was expected to result in the lowest 
effect in terms of bacterial load reduction, whereas both, antagonists 2 and 4 (at 1.25 
and 10 mg/kg) should result in a more pronounced bacterial reduction and antagonist 
4 (10 mg/kg) should be the most effective. In Figure 12 the numbers of colony 
forming units (CFU) at 3 hpi after a preventive treatment with the three antagonists 
as well as the antibiotic ciprofloxacin (CIP, applied s.c., 8 mg/kg, 10 min before 
infection) are compared to an untreated control group in bladder (A) and kidneys (B).  
 
 
Figure 12. CFU/ml of homogenized bladder (A) and kidneys (B) of infected mice treated either with different 
antagonists or ciprofloxacin (CIP). Results were compared to untreated controls or a control group, which 
received the vehicle formulation of antagonist 4 (5% DMSO in PBS containing 1% Tween 80), termed controls 
formulation. Bars represent median values. N=11 for controls, n=6 for the antagonists 2, 3, and 4 1.25 mg/kg, n=8 
for 4 10 mg/kg, and CIP, and n=4 for controls formulation. (Significance testing: Kruskal-Wallis test, Dunn’s post-
test, P < 0.05). DL: detection limit (dashed line). 
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Compared to the median CFU/ml of Log10 6.6 in the control group, bladder colony 
counts were reduced in the groups treated with the antagonists 2 and 4 as well as 
with CIP, but only moderately with 3. However, only treatment with antagonist 4 
(10 mg/kg) showed a statistically significant reduction of bladder counts (Kruskal-
Wallis test, Dunn’s post-test, P< 0.05) compared to the control group and the controls 
formulation. With antagonist 4, a 3 Log10 CFU/ml reduction was achieved, compared 
to a 2 Log10 CFU/ml reduction for the CIP treatment group. No significant decrease of 
CFU counts was observed in kidneys, indicating that the primary compartment of 
action of the FimH antagonists is the bladder. Although not significant, CIP 
decreased kidney colony counts by 2.3 Log10 units. 
 
The results of the PK study and the acute bladder infection study with antagonist 4 
were published in PAPER I.190 
 
Overall, these results indicate that the MAC90 determined in the in vitro assay 
together with in vivo PK indeed provide a reference for an effective reduction of 
bacteria within the first three hours in the bladder. Antagonist 3, which did not reach 
MAC90 levels in PK studies, showed nearly no effect in the bladder compared to the 
controls. On the other hand, both, antagonists 2 and 4 (in the higher dose), showed 
reasonable (Log10 1.4) to excellent (Log10 3) CFU/ml reductions in the bladder 
compartment. Furthermore, the therapeutic effect is mirrored in the Cmax/MAC90 ratio. 
As mentioned earlier, antagonist 2 exceeded the MAC90 by approximately a factor of 
9 at the maximum concentration levels (3 h post application), which is within the 
infection time studied. Antagonist 4 exceeded the MAC90 by approximately 300-fold 
in a dose of 10 mg/kg. Besides, the bacterial reduction of 4 in the bladder was 
approximately doubled when the higher dose (10 mg/kg) instead of the lower (1.25 
mg/kg) was applied. Therefore, an effective treatment needs concentrations 
exceeding MAC90, with the magnitude of Cmax/MAC90 being important.  
 
Bacterial loads in the kidneys were only moderately reduced by antagonist 3 (-0.93 
Log10 CFU/ml) and antagonist 4 at the lower dose (-1.1 Log10 CFU/ml). In the 
kidneys, α-D-gal-1-4-β-D-gal globosides are important for UPEC binding via PapG 
class II adhesins.23 PapG is therefore not targeted by FimH antagonists. In addition, 
as discussed in chapter 3.3., C3H mice are susceptible towards vesicourethral reflux, 
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which allows a fast development of kidney infections.214 Nevertheless, the clearance 
of bacteria from the bladder should also limit the number of ascending bacteria in 
later infection stages. 
 
The infection itself might influence the PK properties of FimH antagonists. Therefore, 
urine concentrations of antagonists at two time-points during the infection were 
analyzed (0.6 and 3.67 h after application). The urine concentrations matched 
previously determined PK concentrations for all antagonists (data not shown). These 
results are an indication that the infection does not influence the PK properties of the 
tested antagonists. 
 
Since antagonist 4 proofed to be the most effective in the acute bladder infection, it 
was chosen for further evaluations, which are presented in MANUSCRIPT I:  
 
“Treatment regimens of FimH antagonists against urinary tract infection – PK/PD of 
an anti-adhesive therapy” 
 
Anja Sigl, Priska Frei, Katharina Mayer, and Beat Ernst 
 
Shall be submitted to Antimicrobial Agents and Chemotherapy 
 
My contributions: 
• The designing, planning, and performing of all studies and their evaluations.  
• Writing of the entire manuscript. 
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4.3.2. Application of FimH antagonists in CAUTI (MANUSCRIPT II) !
MANUSCRIPT II 
 
Since type 1 pili are important for biofilm formation (see Chapter 1.7.) FimH 
antagonists could be therapeutically useful to prevent biofilm formation of UPEC on 
catheter surfaces and reduce the risk for CAUTI. Therefore, FimH antagonists were 
screened for their potential to prevent biofilm in a conventional CV-staining assay 
and proofed to be effective. The assay format was further adjusted to more closely 
mimic human situation. This ultimately led to the deep-well catheter assay, which 
allows the screening of antagonists against biofilm formation on the surface of 
catheters in pooled human urine. The results are summarized in MANUSCRIPT II: 
 
“The preventive effect of FimH antagonists on biofilms formed on a catheter surface” 
 
Anja Sigl, Justyna Nowakowska*, Oliver Schwardt, Lijuan Pang, Priska Frei, Nina 
Khanna*, and Beat Ernst 
 
*Infection Biology Laboratory, Department of Biomedicine, University and University 
Hospital of Basel, Switzerland 
 
Shall be submitted to Antimicrobial Agents and Chemotherapy 
 
My contribution: 
• Expand and amend the preliminary experiments of Justyna Nowakowska, e.g., 
testing antagonists in the same set-up in LB medium. 
• Adapt the testing of antagonists in human urine. 
• Develop and perform the catheter assay. 
• Writing the entire manuscript. 
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4.4. The influence of the FimH affinity state upon in vivo infection 
(parts of master theses of Manuel Starck, Nathalie Lüdin, and 
Rachel Zimmermann) 
 
Several mutations can influence the binding pocket of the FimH lectin domain of 
UPEC and affect the affinity of the bacteria towards soluble or fixed ligands (see 
Chapter 1.9.).86,199,205 Most of the published work so far was performed using UTI89, 
which has a FimH locked in the high affinity state, resulting in a residence time of 
antagonists on the FimH CRD of approximately 3.6 hours, which is atypical for 
carbohydrate-lectin interactions.229  
 
When interfering with the binding to the bladder epithelium, soluble FimH antagonists 
are confronted with all three naturally occurring FimH conformations (affinity states, 
chapter 1.9.). Therefore, several antagonists were screened against different UPEC 
strains using the established in vitro cell infection assay (chapter 3.2. and PAPER I) 
and IC50 and MAC90 were recorded (Table 3).207 Additionally to UTI89, also J96 
(kindly received from Prof. James R. Johnson, University of Minnesota Medical 
School), and CFT073 (kindly received from Prof. Harry L.T. Mobley, University of 
Michigan Medical School) were used.230,231 Both strains were transformed with the 
pBR322GFP plasmid using electroporation to express GFP. The procedure was 
described by Scharenberg et al. and was previously used for UTI89.207 
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Table 3: IC50 and MAC90 of several antagonists against UTI89, J96, and CFT073 determined in the in vitro cell infection assay. Part of these experiments were performed by 
Nathalie Lüdin and Rachel Zimmermann, two former master students. Indicated are mean values of individual measurements with SD. For evaluation, only living cells were 
analyzed. N.d., not determined, *1 Resulting cell viability below 20%, *2 Cell viability below 20% in a few samples. 
Antagonist name Structure UTI89 J96 *1 CFT073 
  IC50 MAC90 IC50 MAC90 IC50 MAC90 
n-heptyl α-D-
mannopyranoside  
6.9± 3.9 
µM 
14.8 ±11.5 
µM 
2.1 ± 1.5 
µM 
18.8 ± 13.6 
µM 
17.4 ± 6.2 
µM 
156.4 ± 
55.6 µM 
JXH-III-047 
(3 in 4.3.1.) 
 
3.9 ± 2.8 
µM 
18.1 ± 
12.3 µM 
n.d. n.d. 
MH17 
(2 in 4.3.1.) 
 
0.21 ± 
0.13 µM 
3.1 ± 1.6 
µM 
n.d. n.d. 
JXH-III-029 
 
95 ± 63 
nM 
395 ± 370 
nM 
21 ± 3.4 
nM 
188 ± 31 
nM 
18.9 ± 5.4 
nM 
170 ± 49 
nM 
JXH-IV-084 
 
147 nM 1.8 µM 
0.25 ± 
0.11 nM 
2.2 ± 1 nM 
58 ± 55 
nM 
530 ± 500 
nM 
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Antagonist name Structure UTI89 J96 *1 CFT073 
  IC50 MAC90 IC50 MAC90 IC50 MAC90 
JXH@087 
 
57 nM 880 nM 
1.3 ± 1.3 
nM 
12.2 ± 11 
nM 
28 ± 15 
nM 
319 ± 51 
nM 
WS495 
 
n.d. 39 nM 17 µM n.d. 
KMFH58 
(4 in 4.3.1., 10j in PAPER I, 
MANUSCRIPT I, 5 in 
MANUSCRIPT II)  
0.11 ± 0.1 
µM 
0.95 ± 1 
µM 
0.56 ± 0.3 
µM 
4 ± 5.4 µM 
1.26 ± 
0.73 µM *2 
18 ± 22 
µM *2 
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Clearly, affinities of individual antagonists vary between strains, likely due to the 
affinity state of the FimH. Although J96 showed the best affinities for many of the 
antagonists, the values are biased. J96 accounted for the highest cell toxicity and 
resulted in low viable cell counts in many samples. Often, fewer than 20% of all cells 
were still alive and could be evaluated, which might have decreased the GFP signal 
and led to a lower IC50 or MAC90. This might account to some extent for the high 
standard deviations reported for J96 in Table 3. Further difficulties of the assay, 
contributing to the high variations of the reported values, are discussed in chapter 
3.2. 
 
JXH@087 resulted in the highest affinity for all three tested strains, but suffers from 
low solubility (2.4 µg/ml, determined by Jacqueline Bezençon). Applied in the acute 
bladder infection model (3h infection), JXH@087 failed to reduce the bacterial load 
of UTI89, J96, and CFT073 (results not shown). It remains unclear, whether this is 
due to the low solubility, limiting availability of JXH@087 in the urine, or its low 
residence time. More likely, the outcome of the in vivo experiment is resulting from a 
combination of the above parameters and not only a single reason.  
 
Within another master thesis, Manuel Starck sequenced all FimH of the strains used 
in this thesis and compared the amino acid mutations. Figure 13 shows a crystal 
structure of the FimH protein in the low affinity state (E. coli K-12), where the 
positions of amino acid differences within the lectin domain of the strains of interest 
are marked. In the adjacent table, the mutations are indicated.  
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Figure 13. The protein structure of FimH (E. coli K-12, PDB code 4J3O) with the indicated positions of the 
mutated amino acids summarized in the table on the right. Only the differences within the lectin domain are 
shown. The picture was kindly provided by Christoph Sager (PyMol).  
 
As introduced in chapter 1.9., single mutations can have an allosteric effect upon 
affinity of the mannose binding site by influencing the tertiary structure of the protein, 
which ultimately leads to a more shallow or tighter binding pocket. This affinity may 
influence the initial binding strength to the uroplakin on bladder cells of UPEC in the 
first step of the infection. It was estimated that the Kd of the low affinity state to D-
mannose is approximately 300 µM compared to 1.2 µM of the high affinity state.198 
 
Figure 13 represents the differences in amino acid residues between four strains 
(UTI89, J96, CFT073, and C175-94, the latter was provided by Dr. Carsten Struve, 
Statens Serum Institut, Denmark) within the FimH lectin domain. Among those 
mutations, positions 27, 62, and 163 were previously described as important for 
mannose binding. Typically, A27V in combination with V163A resulted in decreased 
CFU counts in the bladder in vivo. Furthermore, both A62S or A27V together with 
V163A resulted in fewer IBCs in the bladder of mice.86 Likewise, A62S was also 
associated with a reduced binding to mannose and diminished biofilm formation.86,232 
However, the authors also concluded that the mannose binding ability does not 
represent in vivo fitness.86 On the other hand, the combinations of A/A/V (UTI89) and 
A/S/A (CFT073) on positions 27, 62, and 163 were not found in healthy feces, where 
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A/S/V (C175-94) was most common.205 Therefore, these positions were proposed to 
be subject to positive selection for an increased fitness in the urinary tract.86,233  
 
The affinity state influences initial binding to surfaces and consequently also the 
ability for surface exploration. All factors in combination, i.e., binding strength, 
residence time, and exploration of a surface can have advantages or disadvantages 
in certain circumstances, which creates a natural selective mechanism. As presented 
in MANUSCRIPT II, the ability for strong mannose binding selects for good biofilm 
formers, which was also confirmed by Hung et al.133 Since attachment and biofilm 
formation is an important part in UTI, the virulence of different strains might partly be 
connected to the affinity state of their FimH. To test the virulence of different strains, 
mice were infected with UTI89, ΔfimUTI89 J96, and C175-94 and their bacterial load 
at 24 hpi and 72 hpi was analyzed (Figure 14). 
 
!
Figure 14. CFU in urine (A), bladder (B), and kidneys (C) after 24 or 72 hours of infection with different bacterial 
strains indicated on the x-axis. A line in each group indicates the median. 
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UTI89 resulted in high urine and bladder CFU counts at 24 hpi (7 and 6.5 Log10 
CFU/ml, respectively), but bacterial loads dropped markedly at 72 hpi, with bladder 
counts at 3.4 Log10 CFU/ml (Figure 14A and 14B). Thus, UTI89 caused a rapid 
bladder infection with initial high bacterial burden, which greatly decreased over time. 
Instead, J96 resulted in an opposite infection course with low bacterial loads in the 
bladder at 24 hpi (5.3 Log10 CFU/ml), which dramatically increased at 72 hpi, with 
7.1 Log10 CFU/ml (Figure 14B). Thereby, it caused uniformly high bacterial counts in 
the bladder of all six mice tested. C175-94 resembled the course of UTI89, with high 
counts in urine and bladder at 24 hours (7.6 and 6.6 Log10 CFU/ml, respectively) 
and low counts at 72 hpi with a median of 4.4 Log10 CFU/ml in the bladder. However, 
the bladder colony counts of C175-94 were scattered over a broad range within the 
six mice tested (Figure 14B).  
 
In the kidneys (Figure 14C), all strains reached similarly high counts, which were 
stable over the 72 hours of infection, and leveled at approximately 4 Log10 CFU/ml. 
The mutant strain ΔfimUTI89, lacking functional type 1 pili, resulted in low bladder 
and kidney infections (Figure 14B and 14C), which was not stable over time. This 
shows the importance of type 1 pili for the establishment of a UTI, but also for 
persistence.  
 
Overall, since bacterial adhesion is a crucial step in UTI, the affinity state of FimH 
might be of great importance and governs the infection course not only at the 
beginning, but likely for the whole duration of the infection. All tested strains showed 
a different trend concerning bacterial loads, most obviously seen in the bladder. All 
strains established a similarly high kidney infection, which was stable over time. 
Kidney infection is independent of FimH. Totsika et al. reported a chronic cystitis in 
40% of C3H/HeN mice after two weeks of infection with EC958.187 Conceivably, also 
this course of infection might be specific for EC958 and different in human beings. Of 
course, it is not possible to completely assess the infection course of all tested 
bacteria based on only two time points, but it indicates that every bacterium has a 
different time course of infection, which might require a different treatment scheme 
with FimH antagonists.  
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Yet, the infection time course is not only dependent on the FimH state, but on other 
virulence genes and on the host’s health state, for example. In any case, revealing 
the influence of the FimH mutations upon treatment options and affinities of FimH 
antagonists remains the subject of future investigations. 
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ABSTRACT 
 
Anti-adhesion therapies, a new therapeutic approach to treat infectious diseases, 
avoids killing of the pathogens, reduces selective pressure and therefore the 
development of resistances. In urinary tract infections (UTIs), uropathogenic E. coli 
(UPEC) use FimH-adhesins located at the tip of type 1 pili for the attachment and 
invation to and into urothelial cells of the host. This adhesion process is a 
prerequisite for invasion, colonization, and biofilm formation. FimH antagonists 
provide a novel strategy for preventing UTI by impeding the interaction of FimH with 
the urothelial ligand. In this study, the previously published 3′-chloro-4′-(α-D-
mannopyranosyloxy)biphenyl-4-carbonitrile (Kleeb, S. et al. J. Med. Chem. 58, 
2221–2239, 2015) was applied to study the potential for a therapeutic application 
within the UTI infection cycle. This includes a long-term preventive study (24 h), 
different treatment regimens, and combination therapies with ciprofloxacin (CIP). 
Thereby, an effective therapeutic outcome was governed by a specific concentration-
MAC90 (minimal anti-adhesive concentration) ratio, which was most effective before 
the intracellular growth phase and after bacterial egress from infected cells. A single 
preventive dose was effective up to 12 hours after infection and resulted in a 2.2 
Log10 CFU/ml decrease of bacterial colonies in the bladder. Also, the antagonist was 
very effective in a combination therapy with CIP, clearing the bladder from almost all 
bacteria compared to CIP alone. Overall, the 3-chloro-4’-cyanobiphenyl α-D-
mannopyranoside proofed effective in different treatment set-ups, where the effect 
was governed by an effective concentration/MAC90 magnitude and the duration 
within the infection. 
 
INTRODUCTION 
 
With increasing antimicrobial resistance rates worldwide, anti-adhesive therapies 
could provide a new strategy to combat bacterial infections. However, this new mode 
of action poses new challenges for optimal treatment regimens, as the relationship of 
drug concentration and efficacy is not yet established. Nevertheless, the anti-
adhesive approach was successfully applied in humans and prevented urinary tract 
infection (UTI). It was shown that prophylaxis with high doses of D-mannose reduced 
the recurrence rate of UTI to the same extent as prophylaxis with nitrofurantoin (1). 
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UTI is a highly prevalent infection, affecting 50% of women at least once in their 
lifetime. Moreover, a recurrence rate of 25% within 6 months is challenging any UTI 
treatment and can rapidly lead to resistances (2–4). Up to 90% of the community 
acquired UTIs are caused by uropathogenic E. coli (UPEC) (3, 5). UPEC possesses 
several virulence factors, which enhance the urologic infection potential. One of the 
most important virulence factors are type 1 pili. With the lectin FimH, located at the 
tip of the type 1 pili, the bacteria bind to the highly mannosylated glycoprotein 
uroplakin 1a on the luminal bladder cell surface and initiate the infection cascade (6–
8). Infections with strains unable to express type 1 fimbriae show a 100-1000 fold 
reduced bacterial load in the bladder (9).  
The pathogenic cycle was divided into three stages according to the formation of 
intracellular bacterial communities (IBCs), which are termed as early, middle, and 
late IBCs (10). The initial attachment and invasion process (up to 3 h post infection, 
early IBC) is followed by an intracellular replication in a biofilm like structure (4-8 h 
post infection, middle IBC) and ultimately results in new bacterial egress (starting at 
12h post infection, late IBC) (10–13). Back in the bladder lumen, bacteria can initiate 
a new infection round or infect underlying immature cells, leading to the 
establishment of a quiescent intracellular reservoir (QIR) (14, 10, 12, 15). An 
average middle IBC is built up of approximately 103-105 colony forming units (CFU) 
(10, 12, 15). Bacteria that are able to invade, but do not form IBCs, are rapidly 
cleared from the urinary tract (16). Also, genes important for the establishment of an 
IBC were shown to be positively selected in uropathogenic strains (16, 17). Thus, 
IBCs are important for bacterial persistence and are most challenging to treat. Within 
an IBC, bacteria are protected from urine flow, from immune reactions, and also from 
most antibiotic treatments. IBC formation was described in humans, different mouse 
strains, and also in cultured bladder cells (18, 19). Therefore, mice offer a good 
model to study the pathogenesis of UTI. It was shown that the experimentally 
induced bladder infection in C3H/HeN mice, which were mainly used for UTI studies, 
is most active within the first 24 hours post infection (hpi). After 48 hours, up to 40% 
of infected mice developed a persistent bacteriuria and chronic cystitis, whereas the 
remaining animals cleared the infection (20). 
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FimH antagonists mimic the physiological ligand and target the initial adhesion by 
binding to the FimH lectin, preventing the attachment to the bladder epithelial 
surface. This results in the clearance of the bacteria with urine flow. Compared to D-
mannose, antagonists with improved pharmacokinetic (PK) and pharmacodynamic 
(PD) properties were synthesized and effectively depleted bacterial loads in the 
bladder of mice up to 3 Log10 units (21–25). The anti-adhesive mechanism of action 
offers the possibility for preventive applications. Yet, FimH antagonists could also 
impede bacteria emerging from infected cells from starting a new infection cycle. 
Accordingly, Totsika et al. showed a beneficial effect of FimH antagonists in treating 
recurrent cystitis (26). However, FimH antagonists were so far not characterized for 
their PK/PD characteristics. In other words, it is not clear, how FimH antagonists 
have to be applied to be most effective in the context of the UTI infection cycle. 
 
In our study, the potent para-cyano biphenyl α-D-mannopyranoside (10j in (25)) was 
used to study the effect of a preventive application in a 24-hour infection. The results 
were used to create different treatment regimens, taking into account the infection 
cycle stages. Also, urine concentrations of the antagonist were studied in detail, both 
in uninfected and infected mice. Furthermore, the antagonist was used in a 
combination therapy with ciprofloxacin (CIP). The results presented here should 
assist optimal treatment regimens for future applications of anti-adhesive therapies 
for prevention and/or treatment of UTI in patients.  
 
MATERIALS AND METHODS 
 
Bacterial cultivation. Cystitis isolate UTI89 was kindly provided from the group of 
Prof. Urs Jenal, Biozentrum, University of Basel. For experiments, the strain was 
cultivated overnight at 37°C in 10 ml Luria-Bertani broth (LB, Becton, Dickinson and 
Company, France). For harvesting bacteria, the liquid broth was centrifuged (1857 g, 
10 min) and bacterial pellets were washed three times in Dulbecco’s phosphate 
buffered saline (PBS, Sigma-Aldrich, Switzerland). Bacterial concentrations for 
infection were determined via optical density (OD600) measurements and plating on 
BBL Levine Eosin Methylene Blue (EMB) agar plates (Becton Dickinson, France) in 
serial dilutions to determine the exact bacterial concentration in CFU per ml 
(CFU/ml). 
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Animal studies. For all animal studies, female C3H/HeN (Envigo (former Harlan), 
Netherlands) were used. They were housed two to six animals per cage in a 12h/12h 
light/dark cycle, in specific-pathogen free conditions in the Animal Facility of the 
Department of Biomedicine at the University Hospital of Basel. After one week of 
acclimatization, nine to ten week old mice were used for the experiments. Before and 
during experiments, animals had free access to chow and water at any time. For 
administration volumes and sampling the good practice guidelines were followed 
(27). Numbers of animals used were estimated a priori, depending on the type of 
study, using the G*3Power program (28). All experiments were performed according 
to the regulations of the Swiss veterinary law for animal experimentation.  
 
Pharmacokinetic study. The antagonist was diluted in DMSO (5% of final volume, 
Sigma-Aldrich, Switzerland) and in 1% Tween 80 (Sigma-Aldrich, Switzerland) in 
PBS. For oral application, a gavage (Fine Science Tools, Germany) with syringes 
(Soft-Ject, 1 ml syringes, Henke Sass Wolf, Germany) was used.  
The application was followed by urine sampling at several time points for 24 hours. 
For the PK study in infection, mice were additionally infected 40 min post application. 
Urine samples were directly diluted after sampling with methanol (99%, Acros 
Organics, Chemie Brunschwig, Switzerland) and centrifuged for 11 min at 15700 g. 
The supernatants were transferred to a 96-well plate and the analyte concentrations 
were determined by LC-MS. For the analysis, a 1100/1200 Series HPLC System 
coupled to a 6410 Triple Quadrupole mass detector (Agilent Technologies, Inc., 
USA) with electrospray ionization was used. An Atlantis T3 C18 column (2.1 mm × 
50 mm) with 3 µm particle size (Waters Corp., USA) was used. The mobile phase 
consisted of solvent A (10 mM ammonium acetate, pH 5.0 in 95:5, H2O/MeCN) and 
solvent B (MeCN containing 0.1% formic acid v/v) both delivered at a flow rate of 
0.6 mL/min. Within a total duration of 4 min, the gradient was changed from 95% 
A/5% B to 5% A/95% B during 1 min and held at 5% A/95% B for 0.1 min before 
returning to 95% A/5% B for the remaining 2.9 min. MS parameters such as 
fragmentor voltage, collision energy, and polarity were optimized previously. Data 
was quantified using Agilent Mass Hunter Quantitative Analysis software (version 
B.01.04) and was analyzed using Prism Software (GraphPad Prism). 
 
Papers and manuscripts  MANUSCRIPT I 
! 146 
General procedures for all infection studies. For all infection studies, the drinking 
water of the mice was supplemented with 5% glucose (monohydrate, AppliChem, 
BioChemica, Switzerland) three days before the start of the experiment.  
The antagonist was applied orally, 40 minutes before infection with UTI89 to assure 
sufficient concentration in the bladder. CIP was applied subcutaneously (s.c.) either 
preventively 10 min before infection or as a treatment to the indicated time points at 
a dose of 8 mg/kg, corresponding to a human dose of 500 mg (29). Before infection, 
remaining urine in the bladder was expelled or collected by gentle pressure on the 
abdomen. Mice were anaesthetized in 2.5 vol% isoflurane/oxygen mixture (Attane, 
Minrad Inc, USA) and placed on their back. Infection was performed transurethrally 
using a polyethylene catheter (Intramedic polyethylene tubing, inner diameter 0.28 
mm, outer diameter 0.61 mm, Beckton Dickinson, Switzerland), on a syringe 
(Hamilton Gastight Syringe 50 µl, removable 30G needle, BGB Analytik AG, 
Boeckten, Switzerland). After gentle insertion of the catheter into the bladder, 50 µl 
of bacterial suspension of UTI89 (5.5x109-2.25x1010 CFU/ml) was slowly injected. 
This corresponded to approximately 107-108 CFU per mouse. For the low inoculum, 
mice were infected with 105-106 CFU per mouse. Urine was collected at different 
time points depending on the experiment. Mice were killed by CO2 and bladder and 
kidneys were aseptically removed. Organs were homogenized in phosphate buffered 
saline (PBS) using a tissue lyser (Retsch, Haan, Germany). Serial dilutions of urine, 
bladder, and kidneys were plated on EMB agar plates and CFU were counted after 
overnight incubation at 37°C.  
Remaining urine was used for determination of antagonist concentrations, analyzed 
by LC-MS. Therefore, urine samples were immediately diluted with methanol (99%) 
and centrifuged for 11 min at 15700 g. The supernatants were transferred to a 96-
well plate for LC-MS analysis as described above.  
Generally, data was analyzed using Prism Software (GraphPad Prism). 
 
Long-term prevention study. The para-cyano biphenyl α-D-mannopyranoside (10j 
in 6) was applied orally 40 minutes before infection and mice were killed with CO2 at 
3, 6, 12, and 24 hours post infection (hpi). A control group of four mice per time-point 
was used, which received no treatment. Organs were processed as described 
before. 
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Regimen 1. Antagonist (10 mg/kg) was applied orally 40 minutes before infection, 3, 
and 6 hpi. CIP (8 mg/kg) was given similarly, 10 minutes prior to infection s.c., and 3, 
and 6 hpi for comparison of the treatment efficacy. Mice were killed with CO2 9 hpi. 
The control group received no treatment. During infection, urine was collected and 
urine levels of the antagonist were analyzed by LC-MS. Organs were crushed and 
analyzed as described before. 
Regimen 2. The phosphate prodrug (30) was added to the 5% glucose containing 
drinking water at a concentration of 100 µg/ml 24 hours before infection. With an 
average intake of circa 250 µl per hour for a 25 g mouse (internal surveillance), the 
dose would correspond to 1 mg/kg per mouse and hour. Antagonist concentration in 
the drinking water remained stable throughout the whole experiment (data not 
shown). During infection, urine was collected and antagonist levels were analyzed by 
LC-MS. Organs were crushed and analyzed as described before. 
Regimen 3 and 4. The antagonist (10 mg/kg) was applied at different time points 
relative to infection in combination with CIP (8 mg/kg). The schedules are displayed 
in Figure 3. 
 
RESULTS 
 
A single preventive application of FimH antagonist reduces the bacterial load 
in the bladder for 12 hours. The para-cyano biphenyl α D-mannopyranoside (10j 
from (25), Figure 1B) proofed effective in reducing bacterial counts in a 3 h infection 
with UTI89 by approximately 1000-fold (25). However, this time span only allows to 
study the initial event of an infection cycle, namely attachment and invasion. Also, it 
does not indicate whether the therapeutic outcome is dependent on a time-
dependent (T>MAC90) or a concentration-dependent (Cmax/MAC90) effect, 
respectively. Therefore, the duration of the effect of a single 10 mg/kg application of 
the FimH antagonist was studied in a 24 h experiment. Since urine concentrations, 
as determined in a pharmacokinetic (PK) study, remained over the minimal anti-
adhesive concentration (MAC90, 0.09 µg/ml, (25)) for 24 hours, the effect of the 
antagonist could theoretically last 24 hours (Figure 1A). The MAC90 was determined 
using an in vitro cell infection assay, which was previously published (31, 32). It 
represents the minimal concentration needed for a therapeutic effect.  
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Figure 1. The antagonist exerts a preventive effect up to 12 hours post infection. The para-
cyano biphenyl α D-mannopyranoside (10j in (25), B) was orally applied (10 mg/kg) for the PK and 
the infection study (A). Urine concentrations of the antagonist were sampled at several time points 
and plotted over time (C). The MAC90 is indicated as dashed line. Concentrations stay over the MAC90 
value for 24 hours. The development of the infection over 24 h with (continuous line) and without 
(dashed line) preventive treatment with 10 mg/kg in bladder (D) and kidneys (E) showed a significant 
reduction of bacterial counts in the bladder for 12 hours (Mann-Whitney U test, **, p<0.01, *, p<0.05) 
Shown are median values with the interquartile range. PK: pharmacokinetic, MAC90: minimal anti-
adhesive concentration. 
 
The antagonist reached a Cmax of 112.6 µg/ml at 0.5 h after application and showed 
a slow and steady decrease over time (Figure 1C). The high concentrations were 
beneficial for the therapeutic effect. The single preventive application resulted in a 
CFU reduction for up to 12 hpi, yet, only in the bladder and not in the kidneys. 
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Interestingly, the increase in CFU counts between 3 hpi (3.6 Log10 CFU/ml) and 6 
hpi (4.8 Log10 CFU/ml) in the intervention group and also slightly in the control group 
(from 6.6 to 6.9 Log10 CFU/ml) could indicate a phase of intracellular bacterial 
replication. Bacterial counts of the intervention groups matched control levels after 
24 hours (Figure 1D&E). Likely, this is due to the high bacterial challenge after 
fluxing together with decreasing antagonist concentrations over time, although 
concentrations still remain over the MAC90 (Figure 1C). 
 
Overall, the preventive effect upon a single application of the antagonist was 
measurable for up to 12 hpi. At this time point, bacterial regrowth overwhelmed the 
antagonist effect. Yet, the simple T>MAC90 is not representative for a positive 
treatment outcome. 
 
The antagonist reduces bacterial loads independent of the inoculum. Since 
T>MAC90 is not representative for the therapeutic time-span, the effect might be 
concentration-dependent. Assuming that a positive therapeutic outcome depends on 
the duration of a certain therapeutically relevant concentration-MAC90 ratio, it would 
be interesting to influence either the concentration of antagonist in the urine or the 
MAC90 to change a specific ratio. Therefore, the preventive effect of the antagonist 
was studied using a lower inoculum, which results in a lower number of type 1 pili 
and thus, a lower MAC90 threshold. Mice were preventively treated with 10 mg/kg 
before infection with 105-106 CFU per mouse, which is roughly 100-times less than 
the inoculum for the previous study (107-108 CFU per mouse) (Figure 2). The control 
groups received no treatment and bacterial load in the bladder reached 5.7 Log10 
CFU/ml at 24 hpi (data not shown), which was slightly lower than with the high 
inoculum (7 Log10 CFU/ml). 
Bladder counts of the treated group were reduced from 5 Log10 CFU/ml (controls) to 
2.1 Log10 CFU/ml at 3 hpi (Figure 2A). This is the same 1000-fold reduction at 3 hpi 
as it was achieved with the higher inoculum. At 6 hpi, the difference between 
controls and treated group was only approximately 1.5 Log10 CFU/ml, mainly due to 
the low infection of control groups. Bacterial reduction was also observed in the 
kidneys at 3 hpi (Figure 2B). 
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Figure 2. The therapeutic effect is independent of the inoculum. Preventive oral application of 
FimH antagonist (FA, 10 mg/kg p.o.) and infection with an inoculum of 105-106 CFU per mouse. (A) 
Bladder and (B) kidney CFU counts at 3 hpi and 6 hpi. A line in each group indicates the median. 
(Mann-Whitney U test, *, p<0.05). DL: detection limit (dashed line).  
 
Likely, reaching a certain excess of antagonist compared to the MAC90 is predictive 
for a therapeutic outcome. However, exceeding this effective ratio will not 
proportionally increase the effect. 
 
Different treatment regimens indicate the importance of the concentration 
related to the MAC90 and the possibility for combination therapies. To increase 
antagonist concentrations in urine and therefore prolonging the effective 
concentration/MAC90 ratio, both, a frequent dosing (Regimen 1) and a drinking-water 
prevention (Regimen 2) were studied (Figure 3). In Regimen 1, following a single 
preventive dose (10 mg/kg), two further applications at 3 hpi and 6 hpi were added. 
In Regimen 2, the continuous supply of FimH antagonist via the drinking water could 
increase urine levels even higher and reach a constant level. Furthermore, a 
combination therapy with antibiotics could offer another possibility to apply FimH 
antagonists in UTI treatment. Therefore, ciprofloxacin (CIP), an antibiotic often used 
against UTI (2, 33–36), was studied in two set-ups. Regimen 3 studied the additional 
preventive application to a CIP treatment. In Regimen 4, the antagonist was added 
therapeutically to a CIP treatment of an established infection (Figure 3). 
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Figure3. Treatment set-ups studied using the para-cyano biphenyl α D-mannopyranoside. 
Regimen 1 combines the preventive dose with further therapeutic doses. Regimen 2 is a drinking-
water prevention and Regimens 3 and 4 are combination therapies with ciprofloxacin (CIP, 8 mg/kg, 
s.c.). hpi: hours post infection, FA: antagonist, 10 mg/kg, p.o. 
 
The accumulation of antagonist in urine significantly reduces the bacterial 
counts in the bladder (Regimen 1). The frequent application of antagonist was 
compared to the same treatment with CIP. The results are presented in Figure 4. 
 
 
Figure 4. Frequent antagonist applications lowers bacterial burden in infection. Bacterial counts 
in Log10 CFU/ml in bladder (A) and kidneys (B) after several dosages of 10 mg/kg of antagonist 
(named FA) or 8 mg/kg CIP. In each group, a line indicates the median. Significance testing was 
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performed with Mann-Whitney U test (*, p<0.05, **, p<0.01, ***, p<0.001). DL: detection limit (dashed 
line).  
 
The antagonist treatment resulted in a clear reduction of bladder and kidney colony 
counts compared to the controls. The median reduction in the bladder compared to 
controls was 1.7 Log10 CFU/ml with antagonist and 3.8 Log10 CFU/ml with CIP. Still, 
the reduction in the kidneys was only 0.9 Log10 CFU/ml with antagonist. Also, 
despite the high activity of CIP in both organs, not all bacteria were completely 
eliminated from the bladder.  
 
Urine levels of antagonist were monitored during the infection (Fig. S1). The urine 
levels reached Cmax after the 2nd dosing at 6.6 hpi, with 153 µg/ml (Supplementary 
Figure 1). Therefore, the increased dosing frequency resulted in an accumulation of 
antagonist in the urine, exceeding the Cmax of a single application (112.6 µg/ml) and 
remained constant after the third application at levels above 100 µg/ml.  
 
Overall, the increase in dosing frequency resulted in a significant CFU reduction in 
the bladder. Nevertheless, compared to the long-term effect of a preventive 
application (Figure 1D&E), there was no benefit of additional dosing. Thus, the 
reduction effect was mainly dependent on the initial preventive dose. The long-term 
prevention study showed a 2.2 Log10 CFU/ml reduction at 12 hpi, which is higher 
than the reduction observed here after 9 hours of infection (1.7 Log10 units). 
 
The uptake of antagonist via the drinking water was only effective for a short 
time (Regimen 2). The phosphate prodrug of the para-cyano biphenyl α D-
mannopyranoside (30) was added to the drinking water at 100 µg/ml. The uptake 
(average dosing of 1 mg/kg per mouse per hour) led to concentrations between 7.8 
and 23.2 µg/ml of the antagonist in the urine of the mice, after 24 hours of addition, 
at the time of infection. However, there were high individual differences. After 
infection, concentrations decreased rapidly to 2-7.2 µg/ml at 48 hours (24 hpi) 
(Supplementary Figure 2). Regimen 2 resulted in decreased bladder counts at 6 hpi, 
but not at 24 hpi, probably due to the decreased antagonist concentration at this 
time-point. The antagonist showed no effect upon kidney bacterial load (Figure 5). 
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Figure 5. Drinking water prevention reduces colony counts in bladder at 6 hpi, but not at 24 
hpi. Bacterial counts after a 24 hours preventive application of antagonist (FA) via the drinking water 
at a concentration of 100 µg/ml, corresponding to an approximate average dose of 1 mg/kg per 
mouse per hour. In each group, the median is indicated by a line. Significance testing with Mann-
Whitney U test, *, p<0.5. DL: detection limit (dashed line).  
 
Bladder colony counts were significantly and uniformly reduced by a factor of 
approximately 100 at 6 hpi, whereas the bacterial load in the kidneys was not 
affected by the treatment. At 24 hpi, bacterial counts of the intervention and 
treatment groups equalized between 6.5-7 Log10 CFU/ml in the bladder and around 
Log10 5 CFU/ml in the kidneys.  
 
Urine levels of antagonist after oral application accumulate up to 8 hours. The 
urine levels of the mice in Regimen 2 decreased rapidly after infection, probably due 
to bacterial binding and excretion in a high extent. Urine concentrations of the 
antagonist determined in a PK study do not account for this effect and might 
therefore not correctly reflect the concentrations in an infection. Therefore, urine 
concentrations of the antagonist during infection were analyzed (Figure 6). 
Surprisingly, the analyzed urine levels showed an accumulation between 3 and 8 
hours after oral application, resulting in urine levels of 35 µg/ml at 8 hours. This 
accumulation was not observed in uninfected mice (Figure 6, dotted line). 
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Figure 6. Antagonist concentrations in infected mice accumulate between 3 to 8 hours after 
application. Urine concentration levels over time of infected mice (bold line) compared to non-
infected mice (dotted line, see Figure 1C). Urine levels are similar up to 3 hours, but differ between 3 
and 8 hours after application. In infected mice, levels reach 35 µg/ml at 8 hours compared to 2.3 
µg/ml in uninfected mice. MAC90 (minimal anti-adhesive concentration) is indicated with a dashed line. 
 
FimH antagonists potentiate the effect of CIP in the bladder and the kidneys 
(Regimens 3 and 4). A further application possibility of FimH antagonists would be a 
combination therapy with antibiotics, thereby limiting the antibiotic dose and use. 
Two combination therapy set-ups with FimH antagonist and CIP were studied 
(Figure 3, Regimen 3 and 4). Regimen 3 combines a preventive dose of antagonist, 
followed by a CIP application 3 h after infection. Regimen 4 was used to test the 
possibility of treating an established infection, where the FimH antagonist was 
applied three hours after the CIP dose.  
 
Generally, in both regimens, CFU counts were low in all treated groups, with 
medians between zero and 3 Log10 CFU/ml for bladder and kidneys. Control values 
in the bladder reached 7 Log10 CFU/ml in both regimens, indicating a stable infection 
over the total time range of the experiment. Thus, the bacterial counts were reduced 
by more than half in Regimens 3 and 4. The preventive addition of antagonist 
(Regimen 3) completely depleted bacterial counts from the bladder and nearly 
eradicated bacteria from the kidneys as well. Thereby, group 1 (receiving a 
preventive dose of antagonist) had a 100-fold lower bacterial load than group 2 and 
the same is true for the kidneys (Figure 6).  
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Figure 7. Combining a preventive application of antagonist with CIP eradicates nearly all 
bacteria from the bladder. Bacterial colony counts in Log10 CFU/ml in bladder (A) and kidneys (B) 
resulting of the two different combination regimens 3 and 4 (Figure 3). A line in each group indicates 
the median. For significance, the Mann-Whitney U test was used (**, p<0.01, ***, p<0.001). DL: 
detection limit (dashed line).  
 
However, there was no beneficial effect (Figure 7, Regimen 4) upon addition of 
antagonist in combination to CIP as a therapeutic measure. Although CIP depleted 
bacterial counts in the treated groups compared to controls by half, there was no 
additional reduction of colony counts in bladder, nor kidneys with the antagonist. 
These results confirm the finding that FimH antagonists are most potent upon 
preventive dosing and can strongly enhance antibiotic potency in the bladder and the 
kidneys.  
 
DISCUSSION 
 
To elucidate possible treatment possibilities of FimH antagonists as an anti-adhesive 
therapy for the treatment of UTI, a potent FimH antagonist [para-cyano biphenyl α D-
mannopyranoside, 10j in (25)] was studied in different treatment regimens using the 
well established UTI mouse model (37–39). The antagonist was previously shown to 
reduce bacterial loads in the bladder upon a single preventive oral dose by 1000-fold 
after the first 3h of infection and exceeded the effect of CIP (25). The first three 
hours of an infection are dictated by attachment and invasion of bacteria to and into 
bladder cells (10–13). To expand the previous studies, the preventive effect of the 
antagonist was studied within a 24 hours infection period. The concentration of the 
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antagonist in the urine stayed above the MAC90 for 24 hours, implying a therapeutic 
effect for this time span (Figure 1C). The resulting bacterial counts in the bladder 
revealed an increase of CFU between 3 hpi and 6 hpi in both, the intervention and 
also slightly in the control group (Figure 1D). This could indicate a phase of 
intracellular replication starting after the initial attachment, which is in agreement with 
literature, where a rapid intracellular growth phase of bacteria up to 8 hours after 
infection is reported (10–13). Between 6 hpi and 12 hpi, bacterial loads in the 
bladder of the treated group dropped again, reaching levels similar to 3 hpi, possibly 
because of the fluxing of bacteria from infected cells and re-exposure to FimH 
antagonists. This bacterial egress would be slightly earlier as expected from 
literature reports (approx. 12 hpi (10–13)). This study proofed a response to a 
preventive FimH antagonist treatment up to 12 hpi. Despite the fact that the 
decrease of bacterial CFU in the first 12 hours of an infection is related to the active 
immune response, i.e., cell shedding and the activity of neutrophils, the bacterial 
burden in the control group remained high (11).  
Furthermore, this study also indicates that type 1 pili are re-expressed after invasion 
and fluxing of bacteria, which is consistent with the findings in the in vitro bladder 
infection model by Andersen et al. (15).  
Finally, 24 hpi bacterial counts of the intervention group matched the control counts. 
Thus, T>MAC90 as determined from the PK study, is not the predictive index for a 
positive treatment outcome. 
 
To investigate if the therapeutic outcome depends on the antagonist concentration in 
relation to the MAC90, both parameters, the antagonist concentration and the MAC90 
were varied. First, to lower the MAC90, mice were infected with a lower bacterial 
inoculum, resulting in a lower number of type 1 pili, which have to be blocked to 
prevent the infection. The antagonist proofed to be effective in depleting bladder 
colony counts independent of the inoculum used. The bacterial reduction at 3 hpi 
with a high inoculum (Figure 1 D&E) and the reduction using a low inoculum (Figure 
2) was approximately 1000-fold. Therefore, against expectations, the antagonist did 
not result in a higher bacterial reduction, despite the higher magnitude of the 
concentration/MAC90 ratio. This suggests that if an effective concentration-MAC90 
magnitude is reached, no further proportional increase in bacterial reduction can be 
achieved. 
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Regimen 1 aimed at an accumulation of antagonist concentration in urine to proof 
the concentration-dependent effect. Although antagonist accumulation was 
successful (Figure S1), the resulting bacterial reduction at 9 hpi (1.7 Log10 CFU/ml, 
Figure 4) was lower than at 12 hpi (2.2 Log10 CFU/ml) in the preventive study with a 
single application. However, this goes in hand with the proposed steps of the 
infection cycle. Likely, at 9 hpi the intracellular bacterial replication is ongoing and 
CFU counts mainly result from IBCs, which are not accessible for FimH antagonists. 
Therefore, one should aim at accumulating antagonist concentrations in urine at the 
time of bacterial egress, which would be after 12 hpi, at least in an experimental 
infection, as studied here.  
The superior effect of CIP in regimen 1 might also be attributed to the frequent 
dosing (every 3 hours). CIP is a fluoroquinolone and the effect is governed by the 
area under the curve above the minimal inhibitory concentration (AUC/MIC) (40, 41). 
Frequent dosing increases AUC/MIC and results in high bacterial reductions. 
Although this treatment was rather beneficial for the reduction of bacterial burden, it 
might not be optimal in terms of resistance development or side effects. 
 
Supplying the drinking water with antagonist was assumed to result in a constant 
uptake and expand the time span of the effective concentration/MAC90 ratio. 
Furthermore, this would guarantee the antagonist supply at the critical time-point of 
12 hpi, where bacteria egress from the first intracellular infection round. Yet, the 
reduction was only effective for a short time-span (6 hpi) and did not result in 
decreased colony counts at 24 hpi. The PK urine curves (Figure S2) together with 
the decreasing bacterial loads in the bladder immediately after infection (Figure 5) 
indicate that the antagonist rapidly binds to the bacteria and is consequently 
excreted in high concentrations. Conceivably, the uptake of antagonist via drinking 
water is too low to deal with rapidly increasing bacterial counts, explaining the 
missing effect at 24 hpi. In other words, the effective concentration/MAC90 ratio is not 
reached after bacterial addition due to a decreasing antagonist concentration. 
Furthermore, concurrently, especially during the phase of intracellular replication, 
bacterial numbers rise rapidly, which increases the required MAC90 levels in urine 
after bacterial fluxing. Thus, decreasing antagonist concentrations with a 
simultaneously increasing MAC90 due to increasing bacterial numbers, lead to an 
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inefficient antagonist concentration. Since MAC90 values determined in vitro miss the 
dynamic nature within the infection cycle, the MAC90 represents only the first 
infection events lasting up to 3 hpi, but is not representative for later stages. 
Overall, this strongly indicates that the positive therapeutic effect is dependent on the 
duration of a specific concentration-MAC90 ratio, where both parameters, the 
antagonist concentration and the MAC90, are dynamic within the infection cycle.  
 
Contrarily to the assumption that in infected mice antagonist concentrations 
decrease more rapidly due to bacterial binding and elimination, urine concentrations 
in infected mice showed an accumulation of antagonist between 3 and 8 hours. Yet, 
again, this goes in hand with the described intracellular replication phase of bacteria, 
which starts at approximately 3 hours post infection (10–13). Therefore, after initial 
binding and elimination of bacteria, the antagonist accumulates in the urine during 
the phase of intracellular bacterial growth. Hypothetically, this effect might be 
increased by reduced water uptake of infected mice together with decreased 
urination frequency, which would have to be studied specifically. The high 
concentrations determined here at 8 hours could also be representative for the levels 
at 12-13 hours, where bacterial egress starts. This would explain the therapeutic 
effect up to 12 hpi registered in the long-term prevention study (Figure 1D). This 
supports the previous statement that treatment should focus on a preventive dose 
with subsequent doses every 12 hours to accumulate antagonist concentrations at 
the time, when bacteria are most accessible: when they are in the bladder lumen. 
 
Within the combination therapies, the antagonist showed a high potential in 
improving the therapeutic effect of CIP, but only when applied preventively (Figure 
6). However, compared to the CIP treatment in Regimen 1 (Figure 4), the addition of 
antagonist cleared the bladder from bacteria, which was not achieved with CIP only, 
even with frequent dosing. Additionally, kidney counts decreased markedly within the 
group treated with antagonist and CIP compared to CIP only (Regimen 3, group 1 
compared to Regimen 1, CIP treated group). This confirms the additional effect of a 
FimH antagonist to antibiotic treatment, which was previously reported by Cusumano 
et al. (22). Important for the synergism is the preventive decline of the initial bacterial 
number invading bladder cells and establishing the infection. Normally, high urine 
concentrations of antibiotics are necessary for treating UTI, but the infection can only 
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be completely resolved when high tissue concentrations are reached in the bladder 
and kidneys as well (41). CIP was shown to effectively act on intracellular bacteria 
(42). Therefore, the combination of a FimH antagonist preventing bacterial 
attachment in the urine together with the intracellular and interstitial action of an 
adequate antibiotic therapy is most promising for a fast clearance of UTI. 
 
Generally, it remains questionable, how these results translate from mice to humans. 
Regarding antibiotic research, the PK/PD indices found in animal models normally 
translate to applications in humans (43, 44). However, a classical PK/PD evaluation 
with an indicative PK/PD index (T>MAC90, AUC/MAC90, or Cmax/MAC90) for an 
optimal treatment could not be established in this case. Here, the preventive effect of 
FimH antagonists can best be described by the duration of a specific concentration-
MAC90 ratio. Yet, the MAC90 determined in vitro, is only indicative within the first 3 to 
6 hpi, but not throughout infection because of increasing bacterial counts.  
Furthermore, the correlation of treatment regimens to human applications might be 
different for anti-adhesive compared to antibiotic treatment, as murine models work 
with high inocula and the experimental infection is a rather acute event. Because the 
MAC90 depends on inoculum size, it would be interesting to test a more natural 
course of infection, where only few ascending bacteria initiate the infection. It might 
be that the antagonists bear an even higher potency in prevention and could 
possibly also diminish the infection in the kidneys. Also, frequent dosing combined 
with repeated urination could help to eliminate bacteria more effectively and keep 
antagonist levels high, which, however, is difficult to test in the mouse model. 
Nevertheless, establishing an optimal treatment regimen for anti-adhesive therapies 
is crucial and might decide over failure or success of the therapy, as it was the case 
in clinical studies by Kranjčec et al. or Ukkonen et al. (1, 45). 
 
In summary, an anti-adhesive therapy with FimH antagonists in UTI relies on the 
initial preventive dose, which must be above the defined MAC90 value and the 
achievement of a therapeutic effective concentration-MAC90 ratio and its duration. 
Possibly, bacteria rapidly bind to the FimH antagonist in urine and are eliminated by 
urinal voiding. However, some will be able to invade bladder cells and form IBCs, a 
source for bacterial persistence. In some cases, the immune system is capable of 
eliminating intracellular reservoirs and clearing the infection. Otherwise additional 
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antibiotic therapy might be needed. Therefore, a highly dosed preventive application 
of FimH antagonist might work for a person facing immediate risk for UTI (e.g., 
catheterized patients), whereas a drinking water prevention might help patients 
suffering from recurrent UTIs, where the exact time of recurrence is not clear and low 
bacterial numbers start a new infection. In any case, the preventive application of 
FimH antagonists also offers the possibility for a combination with an antibiotic 
treatment at later stages and could help to diminish antibiotic use in prophylaxis, 
minimizing side effects, and reduce resistance development. 
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ABSTRACT 
 
Catheter-associated urinary tract infections (CAUTI) are frequent complications in 
hospitals and health-care institutions. About 30% of CAUTI are caused by 
uropathogenic Escherichia coli (UPEC), which express type 1 fimbriae on their 
surface, mediating the adhesion to the catheter surface and initiate biofilm formation. 
As a result, this provides a persistent bacterial source for urinary tract infection (UTI). 
The molecular basis of the bacterial adhesion is the lectin FimH located at the tip of 
type 1 fimbriae. FimH antagonists block the FimH-mediated adhesion and 
consequently impede biofilm formation. At low concentrations, FimH antagonists 
successfully prevented biofilm formation of different UPEC strains. However, already 
established biofilms could not be eliminated. In a novel catheter-associated biofilm 
model, the most potent FimH antagonist (para-cyano biphenyl α-D-mannopyranoside 
at concentrations of 6.25 µg/ml) reduced the type 1 pili-mediated biofilm mass of 
UTI89 by 50%, yet, without affecting bacterial viability. Co-application of the FimH 
antagonist and ciprofloxacin provided access to the bacteria within the biofilm for 
ciprofloxacin and resulted in an almost 3 Log10 CFU reduction of viable bacteria. In 
conclusion, FimH antagonists could provide a valuable preventive measure for 
decreasing CAUTIs and potentiating the activity of antibiotics. 
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INTRODUCTION 
 
Urethral catheterization is a major risk factor for the development of urinary tract 
infections (UTIs), one of the most common bacterial infections worldwide (1, 2). 
Approximately 15-20% of patients in hospitals and health-care institutions require 
catheterization and 80% of all hospital-acquired UTIs are related to catheters (3, 4). 
Already a short catheterization of 2 to 10 days leads to a symptomatic catheter-
associated UTI (CAUTI) in one out of four patients (5). Moreover, in more than one 
million annual cases in the United States, CAUTI is responsible for an increase in 
morbidity, for the generation of high treatment costs, and for the development of 
asymptomatic bacteriuria (ABU) (1). In 30% of all CAUTIs, the infection is caused by 
uropathogenic Escherichia coli (UPEC) (6–9).  
 
A key factor of bacterial colonization of the urinary tract is the ability to form biofilms 
(10). Biofilm is a form of complex grouped bacterial growth within an extracellular 
matrix, where the individual cells adhere to each other and/or to surfaces (11). 
Biofilms on urinary catheters provide a survival advantage to the associated bacteria 
resulting in increased tolerance for antibiotics by more than 1000-fold compared to 
planktonic cells and also renders bacteria unsusceptible to biocides (12–15). 
Therefore, bacteria causing CAUTI are resistant towards antibiotics used for UTI 
treatment (16, 17). Several virulence factors are important for biofilm formation and 
urovirulence (18–20). Flagella and type 1 fimbriae are involved in the initiation of 
biofilm formation, allowing for movement along a surface and initial attachment (21, 
22). Thereby, type 1 pili can mediate adhesion to many biotic and abiotic surfaces, 
such as catheters (23, 24). Other adhesins, for example curli, but also the production 
of an exopolysaccharide (EPS) matrix, are essential for maturation and integrity of 
the biofilm structure (21, 22, 25–28). 
 
Type 1 pili are not only a major contributor to the establishment of a UPEC biofilm, 
but also for biofilm maintenance in general and on urinary catheters (21, 22, 29, 30). 
An analysis of urine from catheterized patients and from colonized catheters 
revealed that almost 90% of the bacteria expressed type 1 fimbriae in contrast to 
only 4% in non-catheterized cystitis patients (31, 32). Since deletion of bacteria in 
biofilms is difficult, a preventive approach is requested. Yet, when urinary catheters 
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were conditioned with antimicrobial agents before insertion, contradictory results 
were obtained (33, 34). Nevertheless, a preventive approach towards CAUTI could 
reduce incidence rates and the burden of patients. 
 
FimH antagonists are mannose derivatives, able to prevent biofilm formation by 
blocking the lectin FimH at the tip of bacterial type 1 pili, which mediates binding to 
mannosylated surfaces (21, 22). In addition, it was postulated that the ability for high-
affinity mannose-binding of UPEC selects for strong biofilm formers, which promotes 
a FimH antagonist based treatment (21). As shown in a murine mouse model, FimH 
antagonists offer a valuable option to prevent bacterial persistence on the catheter 
surface (30). 
 
For effective testing of FimH antagonists to prevent CAUTI, a rapid and reliable high-
throughput testing is required. The murine catheter model, as mentioned above, is 
critical to perform, since mice tend to remove the inserted catheters (internal 
communication). In addition to ethical considerations, difficulties also arise from the 
availability of catheter material in the appropriate size. Therefore, to effectively test 
various bacterial strains, representatives of different FimH antagonist families, and 
diverse catheter materials, a high-throughput format for rapid screening is needed. 
Although an in vitro catheter-model has been published previously, it is highly 
laborious, requires large amounts of assay media and test compounds (35). 
 
Here, the systematic analysis of FimH antagonists to inhibit UPEC biofilms was 
studied in an adapted crystal violet (CV) assay in LB medium with several UPEC 
strains. The most potent antagonist was chosen for biofilm prevention studies on a 
catheter surface in pooled human urine. Therefore, a novel in vitro catheter model 
was developed, where biofilm formation was effectively inhibited with low antagonist 
concentrations. Furthermore, the antagonist potentiated the activity of ciprofloxacin 
(CIP). Therefore, FimH antagonists present a valuable option for a preventive 
therapy or in a combination therapy with antibiotics against CAUTI. 
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MATERIALS AND METHODS 
 
Bacterial strains. UTI89 and ΔfimUTI89 were kindly provided by Prof. Urs Jenal, 
(Biocenter, University of Basel, Switzerland), J96 by Prof. James R Johnson, 
(University of Minnesota Medical School, Minnesota, USA (36)), and the strain C175-
94 (37) by Dr. Carsten Struve and Prof. Karen Krogfelt, (Statens Serum Institute, 
Copenhagen, Denmark).  
 
Bacterial cultivation. Bacteria were incubated at static conditions overnight at 37° 
in 10 ml Luria-Bertani broth (LB, Becton and Dickinson, Allschwil, Switzerland). The 
next day, the bacteria were subcultured for additional 4 hours to reach the 
logarithmic phase. Prior to the assays, the optical density (OD600) of the culture was 
measured and bacteria were diluted in assay medium to obtain the desired inoculum 
as indicated in the figure legends. 
 
Collection of human urine. Urine was collected from over 20 healthy male and 
female donors. The collected urine from all donors was pooled, centrifuged (1’857g, 
5 min), sterile filtered (0.2 µm), and stored at -20°C in aliquots. Aliquots were 
defrosted in the amounts that were used for the assay the same day. Before using 
for the assays, aliquots were tested for a normal composition of the urine, using the 
Combur 10 Test® (Roche, Rotkreuz, Switzerland). According to this test, the urine 
used for the assays had the following compositions: specific gravity (1.005-1.015), 
pH (6), leucocyte count (neg.), nitrite (neg.), proteins (neg.), glucose (< 1000 mg/dl), 
ketone (neg.), urobilinogen (normal), bilirubin (neg.), and erythrocytes/hemoglobin 
(neg.). Where indicated, 0.5% casamino acids (CAA) and 0.4% glycerol (both from 
Sigma-Aldrich, Buchs, Switzerland) were added to the urine samples before assays. 
 
96-well plate crystal violet (CV) staining assay. The assay was performed as 
previously described by O’Toole et al., with some modifications (38). In brief, flat-
bottom polystyrene 96-well plates (Falcon, Becton and Dickinson, Allschwil 
Switzerland) were coated with the collected human urine (200 µL) overnight at 4°C. 
The next day, urine was discarded and the bacterial solution (100 µL) was inoculated 
into the wells, either in the absence (controls) or presence of FimH antagonist at the 
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indicated concentrations (100 µl, diluted in PBS, Sigma-Aldrich, Buchs, Switzerland). 
Background levels were determined from urine-coated wells, which contained assay 
medium and PBS and were equally processed. The plates were incubated at 25°C 
for the assigned time. Then, bacteria were discarded and the wells were washed 
twice with PBS. The remaining biofilm was fixed either at 60°C (CV assay in LB) or 
with 200 µl ice-cold methanol (Acros Organics, Chemie Brunschwig, Basel, 
Switzerland) for 10 min and air-drying for additional 15 min (for assays using human 
urine). The biofilm was stained with 0.5% CV (Sigma-Aldrich, Buchs, Switzerland) for 
20 min at room temperature. After removal of the dye, the wells were washed with 
sterile water to remove final traces of the dye. To solubilize the absorbed CV, 200 µl 
of 30% acetic acid (Sigma Aldrich, Buchs, Switzerland) were added to each well 
followed by the transfer of 100 µl into a second 96-well plate. The absorption was 
quantified at 590 nm using a HT synergy reader from BioTek, Lucerne, Switzerland. 
Background absorptions were subtracted from the sample values. Resulting negative 
values were set to zero. The statistical analysis was performed with Prism 
(GraphPad Prism, 5.0) and one-way ANOVA with Dunnett’s post test (CI 95%) to 
compare treated wells to control biofilm. 
 
Microscopy. GFP transformed UTI89 and ΔfimUTI89 (39) were used. The biofilm 
was cultivated in µ-slides 8-well (ibidi, Munich, Germany) in pooled human urine 
containing 0.5% CAA and 0.4% glycerol and kept in a tilted position as described by 
Merritt et al. (40). The slide was incubated at 25°C for 48 hours. Then, the liquid was 
discarded and wells were washed with PBS. Samples were fixed with ice-cold 
methanol for 10 min, followed by drying at room temperature for 15 min. After the 
addition of the mounting medium Vectashield H1000 (VectorLabs, Burlingame, CA, 
USA), the slide was sealed and observed with a 100X magnification on a Delta 
Vision Core microscope and processed with SoftWorx 4.1.2 and Imarisx64 (Imaging 
Core Facility, University of Basel). 
 
Catheter-associated biofilm model. The assay set-up was inspired by the Calgary 
biofilm device (41) and was performed in the same way as the 96-well CV assay, 
described above. Silicone-catheters for children (Uromed AG, Muri AG, Switzerland) 
were cut into consistent pieces of 7 mm or 20 mm (for deep-well assays) using a 
cutting device designed for this purpose, sterilized for 1 hour in 70% EtOH and 
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carefully dried before use. The pieces were fixed to the lid of the flat-bottom 
polystyrene 96-well plates (Falcon, Becton and Dickinson, Allschwil, Switzerland) or 
deep-well plates (Eppendorf, Basel, Switzerland) using nail polish (essence, color 
and go, cosnova, Germany, made in France) as gluing agent (frequently used in 
microscopy, (42, 43)), in such a way that they entered the wells, but did not touch the 
bottom or walls of the wells. A schematic representation of a single well with a 
catheter piece is shown in Figure 1. The numbers represent distances for the short 
and long catheter pieces in millimeters and filling volumes of 200 µl for normal (A) 
and 500 µl for deep-well plates (B), respectively. 
 
 
Figure 15. 96-well assay format with silicone catheter pieces. Catheter pieces (blue) protruding 
into wells filled with urine (yellow). Distances in mm for the normal 96-well plates (A) and the deep-
well plates (B), where a larger urine volume could be used, are indicated. 
 
After incubation, the lid with the catheter pieces was washed and transferred to a 
new plate for staining followed by a washing step to ensure that only the adherent 
bacteria on the catheter surface are quantified and not those on the walls of the 
wells. 
 
For CV staining of catheter pieces incubated in deep-well plates, they were detached 
and transferred to 1.5 ml tubes for further processing. For fixation (methanol), 
staining (0.5% CV) and de-staining (30% acetic acid) solutions of 200 and 500 µl 
were used for the catheter pieces of 7 and 20 mm, respectively. For absorption read-
out of CV, 100 µl of de-staining solution from each well were transferred to a new 96-
well plate.  
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Background absorptions were subtracted from the sample values. Statistical analysis 
was performed with Prism (GraphPad Prism, 5.0) and one-way ANOVA with 
Dunnett’s post test was used (CI 95%) to compare treated wells to the control 
biofilm. 
 
For the determination of the colony forming units (CFU), catheter pieces were 
detached with sterile forceps and transferred into separate tubes for extensive 
washing with PBS. The pieces were washed on the outside and inside by up-and-
down pipetting. This step was repeated twice before the catheter pieces were 
transferred to new tubes containing 1.5 ml sterile PBS. The tubes with catheter 
pieces were sonicated for 5 min (UltraSonic 460/H, Roth, Karlsruhe, Germany) and 
vortexed (Vortex Genie 2, Scientific Industries, New York, USA) at medium speed for 
another minute. Serial dilutions were plated on Eosin methylene blue (EMB) 
containing agar plates (Becton and Dickinson, Allschwil, Switzerland) and incubated 
at 37°C overnight for the evaluation of bacterial counts (per cm of catheter inserted 
into urine and available for colonization) the next day.  
 
RESULTS 
 
Prevention of UPEC biofilm formation by FimH antagonists in a concentration-
dependent manner. Initially, the ability of UPEC to form biofilm was tested using the 
96-well plate CV staining assay (see Methods). A previously established standard 
protocol (38) was adapted to optimise the conditions allowing maximal biofilm growth 
for the strains of interest (data not shown). Strains used for the assays were UTI89, 
J96, and C175-94. The FimH knockout strain ΔfimUTI89 served as a negative 
control. In general, UTI89 formed the most abundant biofilm of all tested strains 
when cultured at 25°C in urine pre-coated wells with Luria-Bertani (LB) broth 
containing 0.5% casamino acids (CAA) and 0.4% glycerol. The pre-coating with 
urine turned out to be essential. 
 
In a next step, five FimH antagonists from different compound classes were tested 
for their inhibitory activity of UPEC biofilm formation (Figure 2). n-Heptyl-α-D-
mannopyranoside (1) was used as a reference compound (44). The FimH antagonist 
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2 with a squarate aglycone (45), 3 with a heterocyclic aglycone (46), 4 (47) and 5 
(48) with a biphenyl aglycone were used as test compounds. 
 
 
Figure 16. Structures of FimH antagonists tested for their activity to inhibit UPEC biofilm 
formation. FimH antagonists from four different chemical classes were studied; n-heptyl αD-
mannopyranoside (1) (reference compound) (44), 2-Chloro-4-[(4-methylpiperazin-1-yl-3,4-dioxocyclo-
but-1-en-1-yl)amino]phenyl αD-mannopyranoside (2) (45), 1-[3-chloro-4-(α-D-mannopyranosyl) 
phenyl]-4-methyl-1H-pyrrole-3-carboxylate (3) (46), 3′-chloro-4′-(αD-mannopyranosyloxy)biphenyl-4-
carboxylate (4) (47), and 3′-chloro-4′-(αD-mannopyranosyloxy)biphenyl-4-carbonitrile (5) (48). 
 
First, the prophylactic and therapeutic potential of the FimH antagonists 1, 2, and 4 
to inhibit biofilm formation was assessed using the optimized CV staining assay. The 
biofilm of UTI89 was either grown in presence of a FimH antagonist for 24 and 48 
hours, respectively (preventive application) or the antagonist was added to a 24-
hours pre-formed biofilm for additional 24 hours of incubation (therapeutic 
application). In both approaches, a concentration-dependent activity could be 
observed. When therapeutically applied, FimH antagonists stopped further biofilm 
formation of the E. coli strain UTI89 at the level of their addition (Figure 3). 
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Figure 17. Influence of FimH antagonists on UTI89 biofilm formation upon therapeutic 
application. FimH antagonists 1, 2, and 4 were added to pre-formed 24 h biofilm (inoculum 1x103 
CFU/well) and incubated for further 24 hours before analysis by CV staining. Dotted line represents 
the 24 h biofilm values. Bars represent means with standard deviations (SDs) from one experiment. 
CV: crystal violet. 
 
In contrast, when FimH antagonist and inoculum were applied simultaneously 
(preventive application), the biofilm mass was clearly reduced compared to the 
control at 24 and 48 hours (Figure 4A and 4B). Notably, ΔfimUTI89 did not produce 
biofilm to a significant extent, suggesting the importance of functional type 1 pili for 
biofilm formation (Figure S1, Supplementary Information). Based on these results, 
the effect of antagonists 1-5 on biofilm formation was tested with additional UPEC 
strains, i.e., J96 and C174-95. Since these strains formed less abundant biofilm 
compared to UTI89, the initial inoculum was increased from 1x103 to 1x104 CFU/ml. 
In order to allow a direct strain comparison, UTI89 and ΔfimUTI89 were re-analyzed 
under these conditions (Figure 4C-4E and Figure S2, Supplementary Information). 
 
Similarly to the effect on UTI89, biofilm formation of J96 was prevented in a 
concentration-dependent manner. For C174-95, a similar effect was detected with 
antagonist 1 (Figure 4E). However, compound 2, 3, 4, and 5 inhibited biofilm of 
C174-95 independent of the concentrations used.  
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Figure 18. Prevention of UPEC biofilm formation by FimH inhibitors. (A and B) To test the 
preventive application, FimH antagonists 1, 2, and 4 were transferred to the wells of a 96-well plate 
together with the inoculum (1x103 CFU/well) and incubated for 24 hours or 48 hours before CV 
staining. Bars represent means with standard deviations (SDs) from one experiment (A) and from at 
least two independent experiments prepared in triplicates (B). (C-D) FimH inhibitors 1-5 were 
transferred to the wells of 96-well plates together with the inoculum (1x104 CFU/well) of different 
strains (C: UTI89, D: J96, E: C175-94) and incubated for 48 hours before CV staining. Bars represent 
means with standard deviations (SDs) from two (compound 3) or three independent experiments 
prepared in triplicates. CV: crystal violet. 
 
In conclusion, none of the tested FimH antagonists was able to clear an established 
bacterial biofilm when applied therapeutically. However, 2, 3, 4, and 5 showed a high 
potency in preventing biofilm formation of different UPEC strains. For all strains, the 
reference compound 1 was characterized by the lowest activity. 
 
Type 1 pili-dependent biofilm formation in human urine. To test the effect of 
FimH antagonists on biofilm formation under realistic conditions, the influence of 
human urine was evaluated in 96-well plate CV staining assay (see Methods). All 
bacterial strains grew well in pooled human urine collected from over 20 healthy, 
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female and male donors (data not shown). The quantitative amount of biofilm mass 
produced by UTI89 and ΔfimUTI89 in urine and in urine supplemented with 0.5% 
CAA and 0.4% glycerol, as used in the previous assay in LB medium, is displayed in 
Figure 5A. 
 
 
Figure 19. Biofilm formation in human urine required bacteria with type 1 pili and was 
enhanced when 0.5% CAA and 0.4% glycerol was supplemented. (A) CV staining of UTI89 and 
ΔfimUTI89 biofilm grown for 48 hours in urine only, urine supplemented with 0.5% CAA and 0.4% 
glycerol compared to LB with 0.5% CAA and 0.4% glycerol (inoculum 1x104 CFU/well). Statistical 
significance was determined with two-tailed t-test (***, p >0.0001). (B) GFP-expressing UTI89 and 
ΔfimUTI89 (39) biofilm formation after 48 hours observed by fluorescence microscopy at 100X 
magnification (bar represent 5 µm for UTI89 and 10 µm for ΔfimUTI89) and respective CV stained 
biofilms images in the wells that were incubated in a tilted position. CV: crystal violet. 
 
Interestingly, in case of UTI89, the CV signal was reduced in urine compared to LB. 
Yet, the absorption values for ΔfimUTI89 were similar in urine only (CV absorption 
0.08) and in urine with supplements (CV absorption 0.08) to the cultivation in LB (CV 
absorption 0.09) indicating a stable background signal (Figure 5A vs. Figure S1, 
Supplementary Information). Although the biofilm growth by UTI89 (positive control) 
and ΔfimUTI89 (negative control) in urine without supplements could clearly be 
distinguished (Figure 5A), an even more pronounced difference was obtained when 
the urine was supplemented with 0.5% CAA and 0.4% glycerol. Thus, for further 
experiments, urine was supplemented with CAA and glycerol. To counter-check 
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these results, biofilms of GFP-expressing UTI89 and ΔfimUTI89 (39) were analyzed 
by fluorescence microscopy (Figure 5B). UTI89 formed a well-structured three-
dimensional biofilm, when incubated for 48 hours at 25°C, whereas the knockout 
strain did not form a biofilm under these conditions. The biofilm of UTI89 was also 
seen by eye in the corresponding wells, when stained with CV. 
 
In summary, UTI89 was able to form a mature biofilm in pooled human urine, which 
was further enhanced by supplementation with CAA and glycerol. Furthermore, the 
dependency of biofilm formation on type 1 pili could be confirmed. 
 
Prevention of UPEC biofilm formation in urine. Next, the most potent FimH 
antagonist, the biphenyl mannoside 5 (Figure 2), was tested for the capacity to 
prevent biofilm formation of UPEC strains in urine supplemented with 0.5% CAA and 
0.4% glycerol in the 96-well plate CV staining assay. Antagonist 5 was selected 
based on its excellent effect in an in vivo UTI disease model (48), but also because it 
exhibited the best effect in the prevention assay performed in LB (Figure 4). The 
activity was compared to reference 1 (Figure 6). 
 
In agreement with the findings in LB medium, UTI89 and J96 turned out to be the 
strongest biofilm formers in urine, whereas biofilm formation by C175-94 was much 
less pronounced. When FimH antagonist 5 was applied, UTI89 and J96 biofilms 
could be reduced by approximately 60% at a concentration of only 6.25 µg/ml 
(Figure 6A and B, respectively). At this concentration, reference compound 1 did 
only marginally reduce the biofilm and background levels could not be reached even 
at the highest concentrations of 100 µg/ml. The reduction of C175-94 biofilm with 
antagonist 5, was concentration-independent, whereas a concentration-dependent 
effect could be observed for reference compound 1. Finally, ΔfimUTI89 did not form 
biofilm, indicated by absorption on the background level (data not shown).  
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Figure 20. Biofilm prevention in human urine. (A-C) Biofilm prevention of 1 (reference compound) 
and 5 against different UPEC strains (A: UTI89, B: J96, and C: C175-94) grown in urine containing 
0.5% CAA and 0.4% glycerol (inoculum 1x104 CFU/well). Similar to the results in LB, the values show 
a concentration-dependent inhibition of biofilm formation. Bars represent means with standard 
deviations (SDs) from three independent experiments prepared in duplicates to quadruplicates. One-
way ANOVA with Dunnett’s post test was used to determine the statistical significance (p) of biofilm 
reduction compared to untreated controls (*, p < 0.05; **, p<0.01, ***, p<0.001). CV: crystal violet. 
 
Prevention of UPEC biofilm formation on catheter surfaces. For simulating the in 
vivo conditions of the bacterial colonization on catheters, a novel in vitro catheter-
associated biofilm model was developed. Catheter pieces were uniformly cut into 7-
mm pieces and attached to the lid of 96-well plate, similar to the Calgary biofilm 
device described by Ceri et al. (41). Catheter pieces protrude into urine-containing 
wells by 2 mm, which allows their bacterial colonization (Figure 7A). Thereafter, the 
biofilm formation on the surface of catheter pieces was evaluated by CV staining.  
 
In this model, both antagonists 1 and 5 were able to prevent the biofilm formation of 
UTI89 in a concentration-dependent fashion (Figure 7B and C, respectively). 
However, compound 5 turned out to be much more potent. At concentrations as low 
as 6.25 µg/ml it reduced the biofilm mass by more than 50% compared to the 
untreated sample (Figure 7B).  
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Figure 21. Prevention of biofilm formation on catheter surfaces. (A) Schematic representation of 
the catheter-associated biofilm model. Catheter pieces were cut into 7mm pieces and attached to the 
96-well plate lid, directly entering single wells. As determined by CV staining of catheter pieces, both, 
5 (B) and 1 (C) were able to prevent biofilm formation (48 h, 25°C, inoculum 1x104 CFU/well). Bars 
represent means with standard deviations (SDs) from three independent experiments prepared in 
duplicates. One-way ANOVA with Dunnett’s post test was used to determine the statistical 
significance (p) of biofilm reduction compared to untreated control (*, p < 0.05; **, p <0.01). CV: 
crystal violet. 
 
Overall, the CV absorption was low (maximum absorption value reached around 
0.06) due to the small catheter surface exposed to the urine (catheter pieces only 
immerged by 2 mm into 200 µl liquid volume). Thus, the surface available for 
bacterial colonization is approximately two times 13 mm2 (internal and external 
surface), neglecting capillary forces, which increases the internal surface available 
for colonization to a small extent. To expand this surface and assess the validity of 
these experiments, longer (2 cm) catheter pieces were cut and inserted into deep-
well 96-well plates, leading to an approximately six-fold increase in catheter surface, 
namely to 0.94 cm2 (internal and external, neglecting capillary forces). With this 
modified model, the biofilm inhibition potential of FimH antagonist 5 was evaluated 
by CV staining as well as enumeration of CFU/cm, indicating the number of bacteria 
per cm of catheter surface entering into the liquid (Figure 8). 
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Despite the increased surface available for bacterial colonization, the maximal CV 
signal was only three times higher, because biofilm formation was mainly observed 
at the air-liquid contact surface of the catheter piece. E. coli is known to form 
oxygen-dependent biofilms, because oxygen supports type 1 pili expression (49, 50).  
 
In summary, CV staining showed the same concentration-dependent inhibition of 
biofilm mass by 5, with a reduction of biofilm by over 50% at a concentration of 
12.5 µg/ml (Figure 8A). Yet, although biofilm mass substantially decreased, bacteria 
remained viable (Figure 8B). Even at the highest concentration of 5 (100 µg/ml), the 
biofilm consisted of over 106 CFU/cm. 
 
 
Figure 22. Prevention of biofilm formation in a modified catheter-associated biofilm model. (A) 
The effect of 5 on UTI89 biofilm formed on catheter pieces with a length of 2 cm was measured with 
CV staining. (B) Viable bacteria on the catheter surfaces (CFU/cm) were enumerated within the same 
assay. Experiments were performed for 48 hours at 25°C with an inoculum of 1x104 CFU/well. Bars 
represent means with standard deviations (SDs) (of Log10 transformed values in B) from three 
independent experiments prepared in duplicates. One-way ANOVA with Dunnett’s post test was used 
to determine the statistical significance (p) compared to untreated control (*, p < 0.05). 
 
In conclusion, 5 showed a high efficacy to prevent biofilm formation of UTI89 on a 
catheter surface, however caused only a small reduction of viable bacteria (Figure 
8). This suggests an influence of FimH antagonists on the structural integrity of the 
extracellular polymeric substances (EPS) or on the bacterial ability to produce EPS. 
However, when EPS is damaged or reduced by FimH antagonists, accessibility of 
bacteria for antibiotic treatment may be improved. 
 
Enhanced effect on biofilm formation by combination therapy. To test this 
hypothesis, a combination therapy with FimH antagonists and antibiotics commonly 
used in UTI was studied in the catheter-associated biofilm model. Therefore, 
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antagonist 5 (indicated as FA) was tested in combination with ciprofloxacin (CIP) and 
trimethoprim-sulfamethoxazole (TMP/SMZ), two antibiotics recommended for UTI 
treatment (51–56). After 24 hours of biofilm formation by UTI89 in the presence of 5 
(preventive application) under the previously used conditions, CIP or TMP/SMZ were 
added at high concentrations of 100 µg/ml or 50 µg/ml, respectively, leading to a 
significantly reduced biofilm mass (Figure 9A). 
 
 
Figure 23. FimH antagonist 5 in combination with antibiotics. CV staining (A) and CFU/cm (B) of 
catheter treated with CIP or TMP/SMZ alone or in combination with 5 (indicated as FA) and CIP or 
TMP/SMZ. Concentrations (in µg/ml) are indicated besides the corresponding therapeutics on the x-
axis. Experiments were performed for 48h at 25°C with an inoculum of 1x104 CFU/well, antibiotics 
were added after 24h. Shown are mean with SDs (of Log10 transformed values for CFU per cm of the 
catheter length inserted into urine, 1.5 cm). Values derived from three independent experiments 
prepared in duplicates. One-way ANOVA with Dunnett’s post test was used for statistical analysis (*, 
p < 0.05; **, p<0.01, ***, p<0.001).  
 
Importantly, antibiotic treatment with CIP and TMP/SMZ alone was not able to 
reduce the biofilm of UTI89 on the catheter surface, suggesting a protective effect of 
the EPS. Furthermore, despite antibiotic treatment, evaluation of CFU/cm (per cm of 
catheter length inserted into urine and available for colonization) revealed a high 
proportion of surviving bacteria (Figure 9B). However, the combination therapy with 5 
and CIP reduced bacterial counts by almost 3 Log10. In contrast, with TMP/SMZ and 
5 the bacterial counts could not be reduced, although the biofilm mass was 
substantially lowered. Moreover, the effect on biofilm mass and bacterial viability was 
not concentration-dependent, suggesting that even low concentrations of FimH 
antagonist and antibiotic in combination are sufficient for decreasing the biofilm. 
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DISCUSSION 
 
In this report we could demonstrate that FimH antagonists are able to successfully 
prevent the formation of UPEC biofilm on various surfaces, importantly, on a catheter 
surface, which is of importance for prevention of CAUTI. FimH antagonists do not act 
on pre-formed biofilms, but inhibit further biofilm growth. This suggests that type 1 pili 
are not only important for the initial adhesion to the urothelial surface, but also for 
cell-to-cell contacts and/or the integrity of EPS as proposed by Rodrigues and 
Elimelech (57), who suggested that type 1 pili are important for the coherence of the 
mannose-rich EPS matrix. However, it also indicates that FimH antagonists are not 
able to permeate a functional biofilm matrix to act on previously formed connections 
between bacteria. 
 
Interestingly, biofilm formation of UPEC is much lower at the conditions present in 
the human body, i.e., in physiological human urine and at 37°C. This suggests an 
anti-biofilm environment in humans, since the biofilm mass in urine was reduced by 
approximately 70% compared to LB. This is in agreement with other reports on poor 
biofilm formation in urine (58). 
 
All tested FimH antagonists were able to reduce biofilm mass of different UPEC 
strains in human urine, tested with the CV staining assay. Nevertheless, the extent of 
biofilm formation was different for each strain. Both, in LB and in urine, UTI89 was 
the best biofilm former opposed to C175-94, which showed low biofilm forming 
ability. Hung et al. correlated the mannose affinity of UPEC with their ability to form 
biofilms (21). Indeed, UTI89 is a strong mannose-binder, whereas C175-94 shows a 
low mannose-binding potential (data not shown). These finding obviously support the 
previous hypothesis on the importance of type 1 pili for the integrity of the EPS. 
 
Whereas antagonist 5 effectively reduced biofilm mass of all tested UPEC strains 
and was able to lower biofilm formation on a catheter surface, its effect on viable 
bacteria within the biofilm was minor. However, combining a preventive application of 
the FimH antagonist 5 with a therapeutic application of CIP after the first 24 hours, 
significantly reduced both, the biofilm mass and numbers of viable bacteria. A 
possible reason for this potent effect might be the disruption of the EPS matrix. By 
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blocking type 1 pili, not only the attachment of cells to a surface is blocked, but also 
the first inter-cellular contacts necessary to establish a biofilm. Besides type 1 pili, 
Ag43, and curli mediate autoaggregation and thus the ability for the formation of 
microcolonies, the starting point for biofilms (26, 59–63). However, since type 1 pili 
are longer organelles than Ag43 or curli, they can and prevent their intercellular 
contact (63). When they are blocked, the smaller adhesive organelles might not be 
able to interconnect to the same extent. Therefore, the decreasing biofilm mass 
indicates a disruption of the integrity of biofilm matrix, leaving the bacteria 
susceptible to antibiotic treatment, as it was demonstrated in this study. 
 
The concept of an anti-adhesive therapy to prevent or reduce biofilms was already 
reported over one decade ago. Pratt and Kolter showed that methyl α-D-mannoside 
is a potent biofilm inhibitor of E. coli (22). In addition, Hultgren et al. reported that 
FimH antagonists inhibit CAUTI caused by UPEC in mice (30). However, since 
UPEC are not the only bacterial strains causing CAUTI and numerous additional 
species might be involved, such as Klebsiella pneumonia or Pseudomonas 
aeruginosa (64), the anti-adhesive concept has a much broader applicability. For 
example, type 1 pili are encoded by many Enterobacteriacea, offering targets that 
might be related to other bacterial infections (65). In a similar manner, biofilms 
related to P. aeruginosa were inhibited and dispersed with fucosides, blocking the 
fucose-specific lectin LecB (66). Thus, a future anti-adhesive therapy for CAUTI 
patients could include a cocktail of several anti-adhesives to successfully prevent the 
adhesion of multiple species and strains. Likely, this combination of several anti-
adhesive drugs could be a valuable option for preventing CAUTIs and would lead to 
decreased antibiotic use and resistance. 
 
In summary, FimH antagonists could provide a novel preventive approach for 
CAUTI. They inhibited biofilm formation on several surfaces and in different media, 
but most important, on the surface of conventionally used silicone catheters in the 
presence of human urine. Furthermore, they potentiated antibiotic effects, even 
when those were added after biofilm formation. Since they are derivatives of the 
naturally occurring D-mannose and rapidly cleared through urine, we estimate the 
possibility of adverse effects in humans to be small.  
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The increasing importance of new therapeutic options for the treatment of resistant 
bacteria thrives the development of new antibacterial agents with novel mode of 
actions. Thus, anti-adhesive therapies could be a valuable option, since they do not 
exert survival pressure and consequently do not promote resistance development. 
Bacterial lectins offer valuable targets for the development of anti-adhesives, as they 
mediate multiple interactions between the pathogen and host structures. 
Furthermore, anti-adhesives are natural sugars or derivatives thereof, hence, they 
should have a low immunogenic potential or should not cause adverse 
reactions.234,235 However, the expression of multiple adhesins on a single bacterium 
might require a cocktail of anti-adhesives for an effective therapy.234–236 Another 
difficulty is the phase variable expression of adhesins, which allows the bacteria to 
adapt and attach in different environmental conditions.237 This might demand an 
exact understanding of the concentrations needed of every individual anti-adhesive 
molecules at the site of action, when applying an anti-adhesive cocktail.  
 
To establish a basic knowledge on the PK/PD relationship of anti-adhesives, FimH 
antagonists were studied in this thesis. Both, their preventive and therapeutic effect 
within UTI were addressed. Thereby, it became clear that they offer a valuable 
preventive option, which work synergistically with antibiotics. They were active in 
mice and depleted bacterial loads by 2-3 Log10 CFU/ml in the bladder for several 
time spans of infection and in different treatment set-ups.  
 
We could reveal that the MAC90 is an important value and represents the initial 
concentration needed in the bladder for a therapeutic effect. The most predictive 
PK/PD index for preventively applied FimH antagonists was the magnitude of the 
Cmax/MAC90 ratio and how long this magnitude is maintained during infection. 
Treatment regimens should aim at increasing the Cmax to keep up with replicating 
bacteria. 
 
Furthermore, FimH antagonists prevented biofilm formation on catheter surfaces in 
concentrations as low as 6.25 µg/ml. Again, they were able to potentiate the 
antibiotic effect. In a next step, the effectivity of biofilm prevention should be 
assessed under flow conditions. 
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Although FimH antagonists have not been tested in humans yet, the therapeutic 
effect might be even higher than in mice, as humans do not have to face the 
challenge of 108 bacteria within a few seconds. Lower bacterial numbers will help to 
more easily reach the Cmax/MAC90 ratio required for positive therapeutic outcome. 
Also, the most successful antagonist presented in this thesis (para-cyanobiphenyl α-
D-mannopyranoside) resulted in urine concentrations over the MAC90 for 24 hours at 
a dose of 10 mg/kg and 1.25 mg/kg. Since mice have a faster metabolism than 
humans, urine concentrations and accumulation of the antagonist in humans might 
even be higher. However, inter-species statements concerning PK are not possible 
at this stage and would need further data.238,239 Furthermore, the therapy with FimH 
antagonists could be combined with frequent liquid intake and urination, which could 
increase the therapeutic success.  
 
Future investigations will have to solve the problem of the different affinity states of 
FimH and their influence upon the infection. Also, combining PapG with FimH 
antagonists seems a promising approach for clearing UTI. 
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